
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="322C300B24F3920500003879CCFD0EF2.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="nnn" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC11160480/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160480/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Neurology&#x000ae; Neuroimmunology &#x00026; Neuroinflammation" /><meta name="citation_title" content="Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies: Implications for Return to Driving" /><meta name="citation_author" content="Anna Rada" /><meta name="citation_author" content="Anne Hagemann" /><meta name="citation_author" content="Charlotte Aaberg Poulsen" /><meta name="citation_author" content="Tobias Baumgartner" /><meta name="citation_author" content="Timea Berki" /><meta name="citation_author" content="Morten Blaabjerg" /><meta name="citation_author" content="Juliette Brenner" /><meta name="citation_author" content="Jeffrey W. Britton" /><meta name="citation_author" content="Andrew Christiana" /><meta name="citation_author" content="Nicol&#x000e1;s L. Ciano-Petersen" /><meta name="citation_author" content="Yvette Crijnen" /><meta name="citation_author" content="Martin Eli&#x00161;&#x000e1;k" /><meta name="citation_author" content="Antonio Farina" /><meta name="citation_author" content="Alec R. Friedman" /><meta name="citation_author" content="Zs&#x000f3;fia Hayden" /><meta name="citation_author" content="Julien H&#x000e9;bert" /><meta name="citation_author" content="Martin Holtkamp" /><meta name="citation_author" content="Zhen Hong" /><meta name="citation_author" content="Jerome Honnorat" /><meta name="citation_author" content="Maria Ilyas-Feldmann" /><meta name="citation_author" content="Sarosh R. Irani" /><meta name="citation_author" content="Stjepana Kovac" /><meta name="citation_author" content="Petr Marusic" /><meta name="citation_author" content="Sergio Mu&#x000f1;iz-Castrillo" /><meta name="citation_author" content="Sudarshini Ramanathan" /><meta name="citation_author" content="Kelsey M. Smith" /><meta name="citation_author" content="Claude Steriade" /><meta name="citation_author" content="Christine Strippel" /><meta name="citation_author" content="Rainer Surges" /><meta name="citation_author" content="Maarten J. Titulaer" /><meta name="citation_author" content="Christopher E. Uy" /><meta name="citation_author" content="Juna M. de Vries" /><meta name="citation_author" content="Christian G. Bien" /><meta name="citation_author" content="Ulrich Specht" /><meta name="citation_publication_date" content="2024/07" /><meta name="citation_issue" content="4" /><meta name="citation_volume" content="11" /><meta name="citation_doi" content="10.1212/NXI.0000000000200225" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC11160480/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC11160480/" /><meta name="citation_pmid" content="38838283" /><meta name="DC.Title" content="Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies: Implications for Return to Driving" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="American Academy of Neurology" /><meta name="DC.Contributor" content="Anna Rada" /><meta name="DC.Contributor" content="Anne Hagemann" /><meta name="DC.Contributor" content="Charlotte Aaberg Poulsen" /><meta name="DC.Contributor" content="Tobias Baumgartner" /><meta name="DC.Contributor" content="Timea Berki" /><meta name="DC.Contributor" content="Morten Blaabjerg" /><meta name="DC.Contributor" content="Juliette Brenner" /><meta name="DC.Contributor" content="Jeffrey W. Britton" /><meta name="DC.Contributor" content="Andrew Christiana" /><meta name="DC.Contributor" content="Nicol&#x000e1;s L. Ciano-Petersen" /><meta name="DC.Contributor" content="Yvette Crijnen" /><meta name="DC.Contributor" content="Martin Eli&#x00161;&#x000e1;k" /><meta name="DC.Contributor" content="Antonio Farina" /><meta name="DC.Contributor" content="Alec R. Friedman" /><meta name="DC.Contributor" content="Zs&#x000f3;fia Hayden" /><meta name="DC.Contributor" content="Julien H&#x000e9;bert" /><meta name="DC.Contributor" content="Martin Holtkamp" /><meta name="DC.Contributor" content="Zhen Hong" /><meta name="DC.Contributor" content="Jerome Honnorat" /><meta name="DC.Contributor" content="Maria Ilyas-Feldmann" /><meta name="DC.Contributor" content="Sarosh R. Irani" /><meta name="DC.Contributor" content="Stjepana Kovac" /><meta name="DC.Contributor" content="Petr Marusic" /><meta name="DC.Contributor" content="Sergio Mu&#x000f1;iz-Castrillo" /><meta name="DC.Contributor" content="Sudarshini Ramanathan" /><meta name="DC.Contributor" content="Kelsey M. Smith" /><meta name="DC.Contributor" content="Claude Steriade" /><meta name="DC.Contributor" content="Christine Strippel" /><meta name="DC.Contributor" content="Rainer Surges" /><meta name="DC.Contributor" content="Maarten J. Titulaer" /><meta name="DC.Contributor" content="Christopher E. Uy" /><meta name="DC.Contributor" content="Juna M. de Vries" /><meta name="DC.Contributor" content="Christian G. Bien" /><meta name="DC.Contributor" content="Ulrich Specht" /><meta name="DC.Date" content="2024 Jul" /><meta name="DC.Identifier" content="10.1212/NXI.0000000000200225" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABABR Antibodies: Implications for Return to Driving" /><meta property="og:type" content="article" /><meta property="og:description" content="Patients with ongoing seizures are usually not allowed to drive. The prognosis for seizure freedom is favorable in patients with autoimmune encephalitis (AIE) with antibodies against NMDA receptor (NMDAR), leucine-rich glioma-inactivated 1 (LGI1), contactin-associated ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160480/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11160480/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2573/">Neurol Neuroimmunol Neuroinflamm</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/461565/">v.11(4); 2024 Jul</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC11160480
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC11160480/pdf/NXI-2023-000585.pdf" class="int-view">PDF (526K)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/11160480/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/11160480/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="11160480" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11160480%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="a4myiZUQhUe5ZprLej5tSTDT4kTUpqpcyeo6WHrg8E8iW2NpFbqVeYAqHpqtvPO3">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11160480%2F&amp;text=Risk%20of%20Seizure%20Recurrence%20Due%20to%20Autoimmune%20Encephalitis%20With%20NMDAR%2C%20LGI1%2C%20CASPR2%2C%20and%20GABABR%20Antibodies%3A%20Implications%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11160480%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160480/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC11160480/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/38838283/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC11160480/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/38838283/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC11160480/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/11160480/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2573/">Neurol Neuroimmunol Neuroinflamm</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/461565/">v.11(4); 2024 Jul</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC11160480
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-nnn.png" alt="Logo of nnn" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="http://nn.neurology.org/" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Neurol Neuroimmunol Neuroinflamm.</span> 2024 Jul; 11(4): e200225. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2024 Jun 4. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1212%2FNXI.0000000000200225" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1212/NXI.0000000000200225</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC11160480</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/38838283">38838283</a></div></div></div><h1 class="content-title">Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABA<sub>B</sub>R Antibodies</h1><div class="fm-subtitle">Implications for Return to Driving</div><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Rada%20A%5BAuthor%5D">Anna Rada</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hagemann%20A%5BAuthor%5D">Anne Hagemann</a>, PhD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Aaberg%20Poulsen%20C%5BAuthor%5D">Charlotte Aaberg Poulsen</a>, PhD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Baumgartner%20T%5BAuthor%5D">Tobias Baumgartner</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Berki%20T%5BAuthor%5D">Timea Berki</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Blaabjerg%20M%5BAuthor%5D">Morten Blaabjerg</a>, MD, PhD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Brenner%20J%5BAuthor%5D">Juliette Brenner</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Britton%20JW%5BAuthor%5D">Jeffrey W. Britton</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Christiana%20A%5BAuthor%5D">Andrew Christiana</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ciano-Petersen%20NL%5BAuthor%5D">Nicol&#x000e1;s L. Ciano-Petersen</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Crijnen%20Y%5BAuthor%5D">Yvette Crijnen</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Eli&#x00161;&#x000e1;k%20M%5BAuthor%5D">Martin Eli&#x00161;&#x000e1;k</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Farina%20A%5BAuthor%5D">Antonio Farina</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Friedman%20AR%5BAuthor%5D">Alec R. Friedman</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hayden%20Z%5BAuthor%5D">Zs&#x000f3;fia Hayden</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=H&#x000e9;bert%20J%5BAuthor%5D">Julien H&#x000e9;bert</a>, MD, MSc, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Holtkamp%20M%5BAuthor%5D">Martin Holtkamp</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hong%20Z%5BAuthor%5D">Zhen Hong</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Honnorat%20J%5BAuthor%5D">Jerome Honnorat</a>, MD, PhD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ilyas-Feldmann%20M%5BAuthor%5D">Maria Ilyas-Feldmann</a>, MD, PhD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Irani%20SR%5BAuthor%5D">Sarosh R. Irani</a>, BMBCh, MA (Oxon), DPhil, FRCP, FEAN, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kovac%20S%5BAuthor%5D">Stjepana Kovac</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Marusic%20P%5BAuthor%5D">Petr Marusic</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mu&#x000f1;iz-Castrillo%20S%5BAuthor%5D">Sergio Mu&#x000f1;iz-Castrillo</a>, MD, PhD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ramanathan%20S%5BAuthor%5D">Sudarshini Ramanathan</a>, PhD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Smith%20KM%5BAuthor%5D">Kelsey M. Smith</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Steriade%20C%5BAuthor%5D">Claude Steriade</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Strippel%20C%5BAuthor%5D">Christine Strippel</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Surges%20R%5BAuthor%5D">Rainer Surges</a>, MD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Titulaer%20MJ%5BAuthor%5D">Maarten J. Titulaer</a>, MD, PhD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Uy%20CE%5BAuthor%5D">Christopher E. Uy</a>, MD, FRCPC, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=de%20Vries%20JM%5BAuthor%5D">Juna M. de Vries</a>, MD, PhD, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Bien%20CG%5BAuthor%5D">Christian G. Bien</a>, MD, and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Specht%20U%5BAuthor%5D">Ulrich Specht</a>, MD</div><div style="display:none" class="contrib-group aff-tip"></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140633132717520_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140633132717520_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140633132717520_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140633132717520_ai" style="display:none"><div class="fm-affl" id="aff-a.k.b.h.ai">From the Department of Epileptology (Krankenhaus Mara) (A.R., C.G.B., U.S.), Medical School, Bielefeld University, Campus Bielefeld-Bethel; Society for Epilepsy Research (A.H.), Bielefeld, Germany; Department of Neurology (C.A.P., M.B.), Odense University Hospital; Department of Clinical Research (M.B.), University of Southern Denmark, Odense, Denmark; Department of Epileptology (T. Baumgartner, R.S.), University Hospital Bonn, Germany; Department of Immunology and Biotechnology (T. Berki), University of P&#x000e9;cs, Medical School, Hungary; Department of Neurology (J.B., Y.C., M.J.T., J.M.V.), Erasmus Medical Center, Rotterdam, Zuid-Holland, the Netherlands; Division of Epilepsy (J.W.B., K.M.S.), Department of Neurology, Mayo Clinic, Rochester, MN; NYU Comprehensive Epilepsy Center (A.C., C. Steriade), New York; French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (N.L.C.-P., A.F., J. Honnorat, S.M.-C.), Hospices Civils de Lyon, H&#x000f4;pital Neurologique, UMR MELIS Inserm 1314 / CNRS 5284, Universit&#x000e9; Claude Bernard Lyon1, France; Department of Neurology (M.E., P.M.), Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic; Department of Neurology (A.R.F., J. H&#x000e9;bert), Columbia University Irving Medical Center (CUIMC)/New York Presbyterian Hospital, New York; Department of Neurology (Z. Hayden), Medical School, University of P&#x000e9;cs, P&#x000e9;cs, Hungary; Division of Neurology (J. H&#x000e9;bert), University of Toronto, Ontario, Canada; Epilepsy-Center Berlin-Brandenburg (M.H., M.I.-F.), Department of Neurology, Charit&#x000e9; - Universit&#x000e4;tsmedizin Berlin, Germany; Department of Neurology (Z. Hong), West China Hospital, Sichuan University, Chengdu, China; Oxford Autoimmune Neurology Group (S.R.I., S.R., C.E.U.), Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom; Department of Neurology and Neurosciences (S.R.I.), Mayo Clinic, Jacksonville, FL; Department of Neurology with Institute of Translational Neurology (S.K., C. Strippel), University Hospital M&#x000fc;nster, Germany; Translational Neuroimmunology Group (S.R.), Kids Neuroscience Centre, Children's Hospital at Westmead; Faculty of Medicine and Health, University of Sydney; Department of Neurology, Concord Hospital, Sydney, Australia; Division of Neurology (C.E.U.), Department of Medicine, University of British Columbia, Vancouver, Canada; and Laboratory Krone (C.G.B.), Bad Salzuflen, Germany.</div><div id="corresp-a.k.b.i.a"><strong>Correspondence</strong> Dr. Rada <a href="mailto:dev@null" data-email="ed.aram@adar.anna" class="oemail">ed.aram@adar.anna</a></div><div id="fn-a.k.b.i.b">Go to <a href="https://nn.neurology.org/content/0/0/e200225/tab-article-info" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">Neurology.org/NN</a> for full disclosures. Funding information is provided at the end of the article.</div><div id="fn-a.k.b.i.c">The Article Processing Charge was funded by the authors.</div><div id="fn-a.k.b.i.d">Submitted and externally peer reviewed. The handling editor was Editor Josep O. Dalmau, MD, PhD, FAAN.</div></div><div class="fm-article-notes hide half_rhythm" id="idm140633132717520_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2023 Oct 10; Accepted 2024 Feb 6.</div></div><div class="permissions half_rhythm hide" id="idm140633132717520_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a>  &#x000a9; 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</div><div class="license half_rhythm">This is an open access article distributed under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</a>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-length="116" class="box-data-avail whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-avl-stmnt" data-ga-action="click_feat_toggler" data-ga-label="Data Availability Statement" class="pmctoggle">Data Availability Statement</a></dt><dd id="data-avl-stmnt" style="display: none;"><p class="p p-first-last">Anonymized data not published within this article will be made available by request from any qualified investigator.</p></dd></dl></div><div id="abstract-a.k.b.s" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.k.b.stitle">Abstract</h2><!--article-meta--><div><div id="sec-a.k.b.s.a" class="sec sec-first"><h3 id="sec-a.k.b.s.atitle">Background and Objectives</h3><p class="p p-first-last">Patients with ongoing seizures are usually not allowed to drive. The prognosis for seizure freedom is favorable in patients with autoimmune encephalitis (AIE) with antibodies against NMDA receptor (NMDAR), leucine-rich glioma-inactivated 1 (LGI1), contactin-associated protein-like 2 (CASPR2), and the gamma-aminobutyric-acid B receptor (GABA<sub>B</sub>R). We hypothesized that after a seizure-free period of 3 months, patients with AIE have a seizure recurrence risk of &#x0003c;20% during the subsequent 12 months. This would render them eligible for noncommercial driving according to driving regulations in several countries.</p></div><div id="sec-a.k.b.s.b" class="sec"><h3 id="sec-a.k.b.s.btitle">Methods</h3><p class="p p-first-last">This retrospective multicenter cohort study analyzed follow-up data from patients aged 15 years or older with seizures resulting from NMDAR-, LGI1-, CASPR2-, or GABA<sub>B</sub>R-AIE, who had been seizure-free for &#x02265;3 months. We used Kaplan-Meier (KM) estimates for the seizure recurrence risk at 12 months for each antibody group and tested for the effects of potential covariates with regression models.</p></div><div id="sec-a.k.b.s.c" class="sec"><h3 id="sec-a.k.b.s.ctitle">Results</h3><p class="p p-first-last">We included 383 patients with NMDAR-, 440 with LGI1-, 114 with CASPR2-, and 44 with GABA<sub>B</sub>R-AIE from 14 international centers. After being seizure-free for 3 months after an initial seizure period, we calculated the probability of remaining seizure-free for another 12 months (KM estimate) as 0.89 (95% confidence interval [CI] 0.85&#x02013;0.92) for NMDAR, 0.84 (CI 0.80&#x02013;0.88) for LGI1, 0.82 (CI 0.75&#x02013;0.90) for CASPR2, and 0.76 (CI 0.62&#x02013;0.93) for GABA<sub>B</sub>R.</p></div><div id="sec-a.k.b.s.d" class="sec sec-last"><h3 id="sec-a.k.b.s.dtitle">Discussion</h3><p class="p p-first-last">Taking a &#x0003c;20% recurrence risk within 12 months as sufficient, patients with NMDAR-AIE and LGI1-AIE could be considered eligible for noncommercial driving after having been seizure-free for 3 months.</p></div></div></div><div id="s1" class="tsec sec"><h2 class="head no_bottom_margin" id="s1title">Introduction</h2><p class="p p-first">Losing the ability to drive is one of the most influential consequences for patients with newly diagnosed epileptic seizures.<sup><a href="#R1" rid="R1" class=" bibr popnode">1</a></sup> The prognosis for seizure remission is very good in patients with the commonest autoimmune encephalitides (AIEs), caused by cell surface antibodies against the N-methyl-<span class="small-caps">d</span>-aspartate receptor (NMDAR), leucine-rich glioma-inactivated protein 1 (LGI1), contactin-associated protein-like 2 (CASPR2), and the gamma-amino-butyric B receptor (GABA<sub>B</sub>R).<sup><a href="#R2" rid="R2" class=" bibr popnode">2</a>,<a href="#R3" rid="R3" class=" bibr popnode">3</a></sup> However, most patients have recurrent seizures in the acute phase of AIE. In contrast to restrictions related to single acute symptomatic seizures, whereafter patients can return to driving after 3&#x02013;6 seizure-free months or even without a driving ban<sup><a href="#R4" rid="R4" class=" bibr popnode">4</a><a href="#R5" rid="R5" class=" bibr popnode">-</a><a href="#R6" rid="R6" class=" bibr popnode">6</a></sup> irrespective of their etiology, driving regulations may view recurrent seizures as &#x0201c;epilepsy&#x0201d; and lead to a driving ban ranging from individually determined intervals to 3 months to 1&#x02013;2 years.<sup><a href="#R6" rid="R6" class=" bibr popnode">6</a></sup></p><p>Reviewing current data on street accident risks of seizures, a European Union expert panel determined that a seizure recurrence risk (ReR) of less than 20%&#x02013;40% for the following year (a metric they termed chance of an occurrence of a seizure in the next year [COSY]) would allow a safe return to noncommercial driving (group 1 licenses).<sup><a href="#R7" rid="R7" class=" bibr popnode">7</a></sup> This risk-based approach formed the basis for the current European directive<sup><a href="#R8" rid="R8" class=" bibr popnode">8</a></sup> and has been used in several international publications on driving issues.<sup><a href="#R9" rid="R9" class=" bibr popnode">9</a><a href="#R10" rid="R10" class=" bibr popnode">-</a><a href="#R13" rid="R13" class=" bibr popnode">13</a></sup> In the United Kingdom, the acceptable risk was adopted and set to a cutoff of 20% by the neurology panel of the Driver and Vehicle Licensing Agency (DVLA).<sup><a href="#R9" rid="R9" class=" bibr popnode">9</a></sup></p><p class="p p-last">Systematic, longer-term data on ReR of patients with NMDAR-, LGI1-, CASPR2-, or GABA<sub>B</sub>R-AIE, who are seizure-free following resolution of the initial illness, are scarce.<sup><a href="#R2" rid="R2" class=" bibr popnode">2</a>,<a href="#R14" rid="R14" class=" bibr popnode">14</a><a href="#R15" rid="R15" class=" bibr popnode">-</a><a href="#R16" rid="R16" class=" bibr popnode">16</a></sup> Few studies have reported on the duration of seizure freedom in patients suffering from AIE associated with LGI1 and NMDAR antibodies.<sup><a href="#R2" rid="R2" class=" bibr popnode">2</a>,<a href="#R16" rid="R16" class=" bibr popnode">16</a></sup> To establish a best estimate of ReR, we collected a multicenter cohort of AIE and performed a pooled analysis of individual patient data. We hypothesized that the seizure ReR in patients with seizures in the context of AIE associated with antibodies against the most frequent extracellular targets (NMDAR, LGI1, CASPR2, and GABA<sub>B</sub>R) is low enough to support limiting the seizure-free driving ban to 3 months. This would bring the driving restriction in line with the 3-month ban currently imposed on persons following a single acute symptomatic seizure, e.g., in Germany and Switzerland.<sup><a href="#R6" rid="R6" class=" bibr popnode">6</a></sup></p></div><div id="s2" class="tsec sec"><h2 class="head no_bottom_margin" id="s2title">Methods</h2><p class="p p-first">We performed a retrospective multicenter cohort study. Between February and September 2021, we invited research groups worldwide known for their expertise in the field of AIE to share pseudonymized original patient data for a pooled analysis. In addition, we asked all collaborating centers for information on other centers with expertise in AIE. We sent a second request to nonresponders 3 months later. Eleven of 14 centers (including our center) agreed to participate. We were able to recruit 3 additional centers through a recommendation from the centers invited in the first round.</p><p>We asked each center to retrospectively identify cases with NMDAR-, LGI1-, CASPR2-, or GABA<sub>B</sub>R-AIE who fulfilled the following inclusion criteria:</p><ul class="unordered" style="list-style-type:disc"><li><div>age 15 years or older at disease onset,</div></li><li><div>1 or more epileptic seizures, and</div></li><li><div>seizure freedom for at least 3 months at any point during the disease course.</div></li></ul><p></p><p>Because of an expected small sample size, AIE due to other antibodies (e.g., GABA-<sub>A</sub>R, mGluR-5, or AMPA-R) were not included.<sup><a href="#R17" rid="R17" class=" bibr popnode">17</a></sup></p><p>We chose 15 years of age as the lower limit, as by the age of 16, after 12 months of follow-up (FU), patients would be eligible for a noncommercial (group 1) driving license in some US states and several countries worldwide.<sup><a href="#R18" rid="R18" class=" bibr popnode">18</a></sup></p><p>For each patient, the following variables were obtained: antibody type; age at first seizure; the duration of up to 4 individual seizure periods; and the time to recurrence after each seizure period or, in case of seizure freedom, to last FU (last contact with the patient). Each seizure period was defined by the date of the first seizure of the respective period and, if at least 3 months of seizure freedom had been achieved, by the date of the last seizure. If a patient did not reach &#x02265;3 months seizure freedom, the respective seizure period was defined as ongoing.</p><p>We asked the centers to include all seizure types including focal aware seizures, although driving regulations sometimes allow patients with focal aware nondisabling seizures to drive. We did not review seizure data received from the collaborating centers because they all are experts in the field of AIEs and seizures. For the same reason, we did not consider the type of immunotherapy, assuming that all centers follow current therapeutic standards in AIE. Antiseizure medication (ASM) was not considered because there are no standardized recommendations for its use.</p><p class="p">The current data on the prognostic relevance of interictal epileptiform potentials in the EEG of patients with AIE with respect to recurrence risk for acute symptomatic seizures are inconclusive; therefore, we did not include this parameter in our consideration.<sup><a href="#R16" rid="R16" class=" bibr popnode">16</a>,<a href="#R19" rid="R19" class=" bibr popnode">19</a><a href="#R20" rid="R20" class=" bibr popnode">-</a><a href="#R22" rid="R22" class=" bibr popnode">22</a></sup></p><div id="s2-1" class="sec"><h3 id="s2-1title">Data Analysis</h3><p class="p p-first">The outcome variable for this study was the time to seizure recurrence, after experiencing 3 months of seizure freedom, the period we determined to be relevant to current driving regulations. We used this variable to estimate the COSY (the probability of a seizure recurrence within the next 12 months) and set the zero point of the time scale to 3 months after the last seizure of a seizure period. This means that patients who are still seizure-free at 12 months on this time scale have not had a seizure for a total of 15 months (3 + 12).</p><p>We used the Kaplan-Meier (KM) method to estimate survival curves with 95% CIs.<sup><a href="#R23" rid="R23" class=" bibr popnode">23</a></sup> This method takes into account that not all patients experience an event (here: a seizure relapse) in the observation time (&#x0201c;censored data&#x0201d;) but uses each patient's data as long as information is available. Each patient is considered as &#x0201c;at risk&#x0201d; to experience the event as long as there is follow-up. We performed separate analyses for the different antibody groups (NMDAR, LGI1, CASPR2, and GABA<sub>B</sub>R) and seizure periods because more than two-thirds of the patients had only 1 seizure period within the observation time. Patients with more than 1 seizure period were therefore included in several analyses.</p><p>In addition, we used regression models to test the effects of potential covariates (sex, age at first seizure, and duration of first seizure period) on the time to seizure recurrence. We tested age at first seizure as a continuous variable and categorized patients into age groups to detect nonlinear effects. Because of the multicenter approach of this study, we used shared frailty models to account for possible heterogeneity between the centers.<sup><a href="#R24" rid="R24" class=" bibr popnode">24</a></sup> These models extend the Cox proportional hazard model by introducing a random intercept which allows the baseline hazard to vary between centers.</p><p class="p p-last">We used SPSS Statistics (v27) and R software (version 4.2.0), specifically the packages &#x0201c;survival,&#x0201d; &#x0201c;survminer,&#x0201d; and &#x0201c;coxme.&#x0201d;</p></div><div id="s2-2" class="sec"><h3 id="s2-2title">Standard Protocol Approvals, Registrations, and Patient Consents</h3><p class="p p-first-last">The study was approved by the Ethics Committee of the University of M&#x000fc;nster, Germany (2018&#x02013;436-f-S). Because data from the authors' own clinical practice were analyzed, patient consent was waived.</p></div><div id="s2-3" class="sec sec-last"><h3 id="s2-3title">Data Availability</h3><p class="p p-first-last">Anonymized data not published within this article will be made available by request from any qualified investigator.</p></div></div><div id="s3" class="tsec sec"><h2 class="head no_bottom_margin" id="s3title">Results</h2><div id="s3-1" class="sec sec-first"><h3 id="s3-1title">Patient Cohort</h3><p class="p p-first">In total, 1,129 patients were retrospectively identified from 14 different international centers (n = 17&#x02013;284 per center). One hundred forty-eight patients were excluded, the most common reason for which was lack of a minimum of seizure freedom for at least 3 months (n = 119/148, 80.4%), leaving 981 patients eligible for analysis (<a href="/pmc/articles/PMC11160480/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>). Most of these patients had antibodies against NMDAR (n = 383, 39.0%) or LGI1 (n = 440, 44.9%). The patients with NMDAR-AIE were on average younger and more often female than the other 3 groups (both <em>p</em> &#x0003c; 0.001, <a href="/pmc/articles/PMC11160480/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). The median observation time across all patients was 30.7 months from the last seizure of the first seizure period to the last FU (interquartile range: 14.1&#x02013;58.8 months, range: 3.0&#x02013;214.2 months). More than 70% of the patients had only 1 seizure period, that is, they had remained seizure-free to the last FU (<a href="/pmc/articles/PMC11160480/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC11160480/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140633157451408"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11160480_NXI-2023-000585f1.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is NXI-2023-000585f1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC11160480/bin/NXI-2023-000585f1.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140633157451408"><a target="object" rel="noopener" href="/pmc/articles/PMC11160480/figure/F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC11160480/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Flow Diagram of Included and Excluded Patients and Reasons for Exclusion</strong><p><sup>a</sup>n = 10 with LGI1 and CASPR2 antibodies; n = 1 with NMDAR and &#x003b1;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) antibodies; n = 1 with NMDAR and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies. VGKC = voltage-gated potassium channel, without being able to specify further.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p>Sex and Age at First Seizure and the Follow-Up Time for Each Antibody for All Included Patients</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">NMDAR</td><td rowspan="1" colspan="1">LGI1</td><td rowspan="1" colspan="1">CASPR2</td><td rowspan="1" colspan="1">GABA<sub>B</sub>R</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">N</td><td rowspan="1" colspan="1">383</td><td rowspan="1" colspan="1">440</td><td rowspan="1" colspan="1">114</td><td rowspan="1" colspan="1">44</td></tr><tr><td rowspan="1" colspan="1">Female, n (%)</td><td rowspan="1" colspan="1">313 (81.7%)</td><td rowspan="1" colspan="1">151 (34.3%)</td><td rowspan="1" colspan="1">5 (4.4%)</td><td rowspan="1" colspan="1">19 (43.2%)</td></tr><tr><td rowspan="1" colspan="1">Age at first seizure, y</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean (SD)</td><td rowspan="1" colspan="1">28.0 (13.3)</td><td rowspan="1" colspan="1">63.2 (11.6)</td><td rowspan="1" colspan="1">64.4 (10.2)</td><td rowspan="1" colspan="1">63.6 (11.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Median</td><td rowspan="1" colspan="1">23.5</td><td rowspan="1" colspan="1">65.0</td><td rowspan="1" colspan="1">66.1</td><td rowspan="1" colspan="1">64.4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Range</td><td rowspan="1" colspan="1">15.0&#x02013;84.2</td><td rowspan="1" colspan="1">24.8&#x02013;92.6</td><td rowspan="1" colspan="1">15.4&#x02013;82.2</td><td rowspan="1" colspan="1">31.6&#x02013;85.1</td></tr><tr><td rowspan="1" colspan="1">Follow-up (mo)<sup>a</sup></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Median</td><td rowspan="1" colspan="1">33.1</td><td rowspan="1" colspan="1">29.7</td><td rowspan="1" colspan="1">37.1</td><td rowspan="1" colspan="1">13.6</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Range</td><td rowspan="1" colspan="1">3.2&#x02013;214.2</td><td rowspan="1" colspan="1">3.0&#x02013;167.1</td><td rowspan="1" colspan="1">3.8&#x02013;108.1</td><td rowspan="1" colspan="1">3.8&#x02013;100.6</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140633157448960"><a target="object" rel="noopener" href="/pmc/articles/PMC11160480/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="fn-a.l.c.b.d.d.a"><p class="p p-first-last">Abbreviations: mo = months; y = year.</p></div><div id="tblfn1"><sup>a</sup>Time from end of the first seizure period to the last follow-up.</div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p>Numbers of Patients per Seizure Period, Antibody, and Last Observed Outcome for Each Period and at Last Follow-Up</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td rowspan="1" colspan="1"></td><td colspan="2" rowspan="1">NMDAR</td><td colspan="2" rowspan="1">LGI1</td><td colspan="2" rowspan="1">CASPR2</td><td colspan="2" rowspan="1">GABA<sub>B</sub>R</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">First seizure period</td><td rowspan="1" colspan="1">383</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">440</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">114</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Seizure-free to last FU</td><td rowspan="1" colspan="1">311</td><td rowspan="1" colspan="1">81.2%</td><td rowspan="1" colspan="1">319</td><td rowspan="1" colspan="1">72.5%</td><td rowspan="1" colspan="1">82</td><td rowspan="1" colspan="1">71.9%</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">79.5%</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Recurrence after &#x02265;3 mo<sup>a</sup></td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">18.8%</td><td rowspan="1" colspan="1">121</td><td rowspan="1" colspan="1">27.5%</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">28.1%</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">20.5%</td></tr><tr><td rowspan="1" colspan="1">Second seizure period</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">121</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;3 mo seizure-free to last FU<sup>b</sup></td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">13.9%</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">22.3%</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">25.0%</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">33.3%</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Seizure-free to last FU</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">61.1%</td><td rowspan="1" colspan="1">73</td><td rowspan="1" colspan="1">60.3%</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">34.4%</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">44.4%</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Recurrence after &#x02265;3 mo<sup>a</sup></td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">25.0%</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">17.4%</td><td rowspan="1" colspan="1">13<sup>c</sup></td><td rowspan="1" colspan="1">40.6%</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">22.2%</td></tr><tr><td rowspan="1" colspan="1">Third seizure period</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;3 mo seizure-free to last FU<sup>b</sup></td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">16.7%</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">38.1%</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">46.2%</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">50.0%</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Seizure-free to last FU</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">55.5%</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">52.4%</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">46.2%</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">50.0%</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Recurrence after &#x02265;3 mo<sup>a</sup></td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">27.8%</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">9.5%</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">7.7%</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">Fourth seizure period</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;3 mo seizure-free to last FU<sup>b</sup></td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">10.0%</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">50.0%</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">100%</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Seizure-free to last FU</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">80.0%</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">50.0%</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">Outcome at last FU (after last seizure period)</td><td rowspan="1" colspan="1">383</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">440</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">114</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Seizure-free to last FU</td><td rowspan="1" colspan="1">369</td><td rowspan="1" colspan="1">96.3%</td><td rowspan="1" colspan="1">404</td><td rowspan="1" colspan="1">91.8%</td><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">86.8%</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">90.9%</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;3 mo seizure-free to last FU<sup>b</sup></td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">3.7%</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">8.2%</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">13.2%</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">9.1%</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140633133388464"><a target="object" rel="noopener" href="/pmc/articles/PMC11160480/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="fn-a.l.c.b.e.d.a"><p class="p p-first-last">Abbreviation: FU = follow-up; mo = months.</p></div><div id="fn-a.l.c.b.e.d.b"><p class="p p-first-last"><em>Note</em>. The numbers and percentages represent the last available outcome for each seizure period. The times to recurrence or last follow-up (FU) vary from patient to patient.</p></div><div id="tblfn2"><sup>a</sup>Patients who had become seizure-free for at least 3 mo after a seizure period and then have had a recurrence.</div><div id="tblfn3"><sup>b</sup>This group includes patients with ongoing seizures and those with &#x0003c;3 mo between the last seizure of this seizure period and the last FU.</div><div id="tblfn4"><sup>c</sup>For one of these patients, the date of the last seizure of the second seizure period is missing. This patient had a recurrence (i.e., entered a third seizure period) 20 mo after the first recurrence and did not become seizure-free until the last FU.</div></div></div></div><div id="s3-2" class="sec"><h3 id="s3-2title">NMDAR Antibodies</h3><p class="p p-first"><a href="/pmc/articles/PMC11160480/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2A</span></a> shows the survival curve of seizure-free patients after a first seizure period with NMDAR-AIE (n = 383), limited to the first 24 months after the required 3-month seizure-free interval. The probability of being seizure-free at 12 months was 0.89 (95% CI 0.85&#x02013;0.92), resulting in an ReR of 0.11 (95% CI 0.08&#x02013;0.15). Even at 24 months, the seizure-free rate was &#x0003e;80% (0.86, 95% CI 0.82&#x02013;0.90). Most patients who experienced a seizure recurrence again achieved another 3-month seizure-free period (62/72, 86.1%, <a href="/pmc/articles/PMC11160480/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>), but their KM estimate at 12 months was lower (<a href="/pmc/articles/PMC11160480/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>), resulting in a ReR &#x0003e;20%. The number of patients entering a third or fourth seizure period was low. They mostly became seizure-free (third period: 15/18, 83.3%; fourth period: 4/5, 80.0%, <a href="/pmc/articles/PMC11160480/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>), and their ReR was low (after the third seizure period, see <a href="/pmc/articles/PMC11160480/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). At the end of follow-up, 96.3% of all included patients with NMDAR-AIE were seizure-free (for &#x02265;3 months) after up to 4 seizure periods (<a href="/pmc/articles/PMC11160480/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). The regression models showed that neither sex nor age at first seizure or duration of the first seizure period influenced the ReR after the first seizure period (<a href="/pmc/articles/PMC11160480/table/T4/" target="table" class="fig-table-link figpopup" rid-figpopup="T4" rid-ob="ob-T4" co-legend-rid=""><span>Table 4</span></a>). For the other seizure periods, the group sizes were too small for subgroup analyses.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC11160480/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140633159147952"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11160480_NXI-2023-000585f2.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is NXI-2023-000585f2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC11160480/bin/NXI-2023-000585f2.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140633159147952"><a target="object" rel="noopener" href="/pmc/articles/PMC11160480/figure/F2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC11160480/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Survival Curve of Seizure-Free Patients After the First Seizure Period</strong><p>Kaplan-Meier (KM) estimates (95% confidence interval) for time to seizure recurrence (in months) after being seizure-free for 3 months in the first seizure period in patients with (A) NMDAR, (B) LGI1, (C) CASPR2, and (D) GABA<sub>B</sub>R antibodies. The dashed green line indicates a seizure recurrence risk of 20%, and the solid red line marks the chance of an occurrence of a seizure in the next year (COSY) 12 months after a 3-month seizure-free period. Abbreviation: cum., cumulative.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><p>Kaplan-Meier Estimates (95% CIs) for Being Seizure-Free at 12 Months for Each Seizure Period (Only if n &#x02265; 10)</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">NMDAR</td><td rowspan="1" colspan="1">LGI1</td><td rowspan="1" colspan="1">CASPR2</td><td rowspan="1" colspan="1">GABA<sub>B</sub>R</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">First seizure period</td><td rowspan="1" colspan="1">0.89 (0.85&#x02013;0.92)<br />[n = 383]</td><td rowspan="1" colspan="1">0.84 (0.804&#x02013;0.88)<br />[n = 440]</td><td rowspan="1" colspan="1">0.82 (0.75&#x02013;0.90)<br />[n = 114]</td><td rowspan="1" colspan="1">0.76 (0.62&#x02013;0.93)<br />[n = 44]</td></tr><tr><td rowspan="1" colspan="1">Second seizure period</td><td rowspan="1" colspan="1">0.78 (0.68&#x02013;0.90)<br />[n = 62]</td><td rowspan="1" colspan="1">0.87 (0.80&#x02013;0.95)<br />[n = 94]</td><td rowspan="1" colspan="1">0.62 (0.44&#x02013;0.87)<br />[n = 23]</td><td rowspan="1" colspan="1">[n = 6]</td></tr><tr><td rowspan="1" colspan="1">Third seizure period</td><td rowspan="1" colspan="1">0.87 (0.71&#x02013;1.00)<br />[n = 15]</td><td rowspan="1" colspan="1">0.83 (0.58&#x02013;1.00)<br />[n = 13]</td><td rowspan="1" colspan="1">[n = 7]</td><td rowspan="1" colspan="1">[n = 1]</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140633159145488"><a target="object" rel="noopener" href="/pmc/articles/PMC11160480/table/T3/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="fn-a.l.c.c.d.d.a"><p class="p p-first-last">The sample size (n) for each seizure period denotes the number of patients becoming seizure-free for at least 3 mo after the respective seizure period (i.e., the number at risk at 0 mo as shown in <a href="/pmc/articles/PMC11160480/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2</span></a> for the first seizure period).</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="T4"><h3>Table 4</h3><!--caption a7--><div class="caption"><p>Results of Univariable Regression Models (Shared Frailty Models) to Predict Seizure Recurrence After the First Seizure Period</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td rowspan="2" colspan="1">Model</td><td rowspan="1" colspan="1">NMDAR (n = 383)<sup>a</sup></td><td rowspan="1" colspan="1">LGI1 (n = 440)<sup>b</sup></td><td rowspan="1" colspan="1">CASPR2 (n = 114)<sup>c</sup></td></tr><tr><td rowspan="1" colspan="1">HR (95% CI) <em>p</em> Value</td><td rowspan="1" colspan="1">HR (95% CI) <em>p</em> Value</td><td rowspan="1" colspan="1">HR (95% CI) <em>p</em> Value</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">A: Sex (male)</td><td rowspan="1" colspan="1">1.02 (0.54&#x02013;1.93) <em>p</em> = 0.949</td><td rowspan="1" colspan="1">1.03 (0.70&#x02013;1.52) <em>p</em> = 0.873</td><td rowspan="1" colspan="1">
<sup>e</sup>
</td></tr><tr><td rowspan="1" colspan="1">B: Age at first seizure (y)</td><td rowspan="1" colspan="1">1.00 (0.98&#x02013;1.02)<sup>d</sup>
<em>p</em> = 0.849</td><td rowspan="1" colspan="1">1.01 (0.99&#x02013;1.03) <em>p</em> = 0.358</td><td rowspan="1" colspan="1">1.03 (0.98&#x02013;1.07) <em>p</em> = 0.244</td></tr><tr><td rowspan="1" colspan="1">C: Age group at first seizure</td><td rowspan="1" colspan="1">Ref. &#x02264;20 y</td><td rowspan="1" colspan="1">Ref. &#x02264;60 y</td><td rowspan="1" colspan="1">Ref. &#x02264;65 y</td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">&#x0003e;20&#x02013;30 y 0.70 (0.41&#x02013;1.22) <em>p</em> = 0.212</td><td rowspan="1" colspan="1">&#x0003e;60&#x02013;70 y 1.10 (0.71&#x02013;1.71) <em>p</em> = 0.657</td><td rowspan="1" colspan="1">&#x0003e;65 y 0.95 (0.46&#x02013;1.94) <em>p</em> = 0.883</td></tr><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">&#x0003e;30 y 0.86 (0.48&#x02013;1.53) <em>p</em> = 0.420</td><td rowspan="1" colspan="1">&#x0003e;70 y 1.66 (1.04&#x02013;2.63) <em>p</em> = 0.032</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">D: Duration of first seizure period (d)</td><td rowspan="1" colspan="1">1.00 (0.999&#x02013;1.001) <em>p</em> = 0.817</td><td rowspan="1" colspan="1">1.00 (0.999&#x02013;1.000) <em>p</em> = 0.193</td><td rowspan="1" colspan="1">1.00 (0.999&#x02013;1.001) <em>p</em> = 0.851</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140633158143280"><a target="object" rel="noopener" href="/pmc/articles/PMC11160480/table/T4/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="fn-a.l.c.c.e.d.a"><p class="p p-first-last">Abbreviations: d = days; HR = hazard ratio; Ref. = reference category; y = years.</p></div><div id="fn-a.l.c.c.e.d.b"><p class="p p-first-last">All models include a random intercept for center. For GABA<sub>B</sub>R, the sample size was too small for reliable regression analysis (n = 44).</p></div><div id="tblfn5"><sup>a</sup>Heterogeneity between centers: the range of relative risks between centers varies between 0.80&#x02013;1.13 (models A and C) and 0.79&#x02013;1.13 (models B and D).</div><div id="tblfn6"><sup>b</sup>Heterogeneity between centers: the range of relative risks between centers varies between 0.64&#x02013;1.46 (model B) and 0.58&#x02013;1.60 (model D).</div><div id="tblfn7"><sup>c</sup>Heterogeneity between centers: the range of relative risks between centers varies between 0.68&#x02013;1.28 (model C) and 0.58&#x02013;1.32 (model B).</div><div id="tblfn8"><sup>d</sup>Proportional hazards assumption not met for &#x0201c;age at first seizure&#x0201d; as a continuous variable.</div><div id="tblfn9"><sup>e</sup>Not done due to the small number of female patients (n = 5/114, 4%).</div></div></div></div><div id="s3-3" class="sec"><h3 id="s3-3title">LGI1 Antibodies</h3><p class="p p-first">The survival curve for patients with LGI1-AIE (n = 440) after the first seizure period (<a href="/pmc/articles/PMC11160480/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2B</span></a>) shows that their COSY was just below the cutoff of 20% (ReR at 12 months: 1&#x02013;0.84 = 0.16, 95% CI 0.12&#x02013;0.196). This held true for patients who had become seizure-free after a second seizure period (<a href="/pmc/articles/PMC11160480/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). Only 2 of 13 patients (15.4%, <a href="/pmc/articles/PMC11160480/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>) had had a recurrence after a third seizure period (10 and 23 months after the 3-month seizure-free interval), and the only patient who was followed up for &#x0003e;3 months after a fourth seizure period remained seizure-free for at least 2 years (last FU). After up to 4 seizure periods, 91.8% of all patients with LGI1-AIE were seizure-free to last FU (<a href="/pmc/articles/PMC11160480/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>).</p><p class="p">While sex and duration of the first seizure period did not correlate with the ReR (<a href="/pmc/articles/PMC11160480/table/T4/" target="table" class="fig-table-link figpopup" rid-figpopup="T4" rid-ob="ob-T4" co-legend-rid=""><span>Table 4</span></a>), seizure recurrence after a first seizure period with LGI1-AIE was related to the age at first seizure: patients aged older than 70 years (n = 131) had a ReR 1.66 times (HR, 95% CI 1.04&#x02013;2.63) that of patients aged 60 years or younger (n = 156). Patients aged between 61 and 70 years (n = 153) did not differ from those aged 60 years or younger (<a href="/pmc/articles/PMC11160480/table/T4/" target="table" class="fig-table-link figpopup" rid-figpopup="T4" rid-ob="ob-T4" co-legend-rid=""><span>Table 4</span></a>). <a href="/pmc/articles/PMC11160480/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3</span></a> shows survival curves for LGI1 patients stratified by age groups. The KM estimates for seizure freedom at 12 months (after the 3-month seizure-free interval) was slightly lower for patients aged older than 70 years at first seizure (0.81, 95% CI 0.74&#x02013;0.88) than for patients aged 70 years or younger (0.85, 95% CI 0.81&#x02013;0.90).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC11160480/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140633158515040"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is NXI-2023-000585f3.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is NXI-2023-000585f3.jpg" src="/pmc/articles/PMC11160480/bin/NXI-2023-000585f3.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140633158515040"><a target="object" rel="noopener" href="/pmc/articles/PMC11160480/figure/F3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC11160480/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Survival Curves of Seizure-Free Patients With LGI1 Antibodies After a First Seizure Period Stratified by Age Group</strong><p>Kaplan-Meier estimates (95% CI) for time to seizure recurrence (in months) after being seizure-free for 3 months in the first seizure period. The dashed green line indicates a seizure recurrence risk of 20%, and the solid red line marks the chance of an occurrence of a seizure in the next year (COSY) 12 months after a 3-month seizure-free period.</p></div></div></div></div><div id="s3-4" class="sec sec-last"><h3 id="s3-4title">CASPR2 and GABA<sub>B</sub>R Antibodies</h3><p class="p p-first-last">For CASPR2 (n = 114) and GABA<sub>B</sub>R (n = 44), the COSY after first seizure period as estimated with the KM method was &#x0003e;20% (95% CI for seizure freedom at 12 months cross the 0.80 lines in <a href="/pmc/articles/PMC11160480/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2, C and D</span></a>). Although the KM estimate for CASPR2 is just above 0.80, it is below this value for GABA<sub>B</sub>R (<a href="/pmc/articles/PMC11160480/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). Cox regression models did not show an influence of age at first seizure or duration of the first seizure period on the seizure recurrence after a first seizure period with CASPR2-AIE (<a href="/pmc/articles/PMC11160480/table/T4/" target="table" class="fig-table-link figpopup" rid-figpopup="T4" rid-ob="ob-T4" co-legend-rid=""><span>Table 4</span></a>). We did not test the effect of patient sex with Cox regression due to the small number of female patients with CASPR2 (<a href="/pmc/articles/PMC11160480/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>), but only 1 of 5 women had a recurrence within the observation time (4 months after the 3-month seizure-free period). For GABA<sub>B</sub>R, the group size was too small for reliable regression analysis. The outcomes for the subsequent seizure periods are summarized in <a href="/pmc/articles/PMC11160480/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Tables 2 and 3</span></a>.</p></div></div><div id="s4" class="tsec sec"><h2 class="head no_bottom_margin" id="s4title">Discussion</h2><p class="p p-first">With this multicenter study, we calculated the seizure ReR for different types of AIE after a predefined seizure-free period of 3 months. Our cohort showed high rates of patients who were seizure-free to last follow-up, ranging from 71.9% (CASPR2-AIE) to 81.2% (NMDAR-AIE) after a first seizure period and are in line with previous findings from smaller cohorts. The same holds true for the age at onset and sex distribution in the different antibody groups.<sup><a href="#R2" rid="R2" class=" bibr popnode">2</a>,<a href="#R3" rid="R3" class=" bibr popnode">3</a>,<a href="#R25" rid="R25" class=" bibr popnode">25</a>,<a href="#R26" rid="R26" class=" bibr popnode">26</a></sup></p><p>After achievement of an initial 3-month seizure-free period, the probability for seizure recurrence for the following year (COSY) was &#x0003c;20% for NMDAR-AIE (89% of patients were seizure-free after 1 year), LGI1-AIE (83.8%), and CASPR2-AIE (82.4%). The 95% CI in the CASPR2-AIE cohort did not exclude a 20% ReR (75.3&#x02013;90.2); however, the group size was considerably smaller than for the NMDAR- and LGI1-AIE cohorts. The GABA<sub>B</sub>R-AIE cohort estimate (76%) failed to reach the 20% limit. Previous studies have not provided all the information required to estimate the COSY.<sup><a href="#R2" rid="R2" class=" bibr popnode">2</a>,<a href="#R14" rid="R14" class=" bibr popnode">14</a><a href="#R15" rid="R15" class=" bibr popnode">-</a><a href="#R16" rid="R16" class=" bibr popnode">16</a>,<a href="#R27" rid="R27" class=" bibr popnode">27</a>,<a href="#R28" rid="R28" class=" bibr popnode">28</a></sup></p><p>Seizure remission rates were somewhat lower in patients who had experienced a seizure recurrence after being seizure-free for at least 3 months. However, in this group, the probability of still being seizure-free at 1 year after achievement of a new 3-month seizure-free interval was 78% (NMDAR), 87% (LGI1), and 62% (CASPR2). The number of included patients in the second seizure periods was too small for further analyses.</p><p>We found no influence of age or sex on seizure ReR, except for a relatively worse prognosis in the group of patients with LG1-AIE older than 70 years. The reason for this result might be due to different therapeutic approaches in this age group; however, we did not consider any type of therapy in this study (see limitations). Another reason could be a different natural history of a LGI1-AIE in that age group or other comorbidities that might influence the course of the disease.</p><p>Seizures occurring during the acute phase of AIE with antibodies against cell surface antigens (such as NMDAR, LGI1, CASPR2, and GABA<sub>B</sub>R) have recently been described to follow the concept of acute symptomatic seizures<sup><a href="#R29" rid="R29" class=" bibr popnode">29</a></sup> instead of seizures due to autoimmune epilepsy which are regarded as unprovoked allowing for the diagnosis of epilepsy.<sup><a href="#R2" rid="R2" class=" bibr popnode">2</a>,<a href="#R3" rid="R3" class=" bibr popnode">3</a>,<a href="#R15" rid="R15" class=" bibr popnode">15</a>,<a href="#R25" rid="R25" class=" bibr popnode">25</a></sup> Our data support this view, confirming high rates of terminal seizure remission.</p><p>Driving restrictions may have major consequences on a patient's educational, professional, and social life. The challenge for driving authorities is to balance the risks of seizure-related accidents for the community and limitations in social participation for the individual with seizures. Defining a threshold value for ReR based on data on general traffic risks provides the opportunity for a more individualized assessment of driving eligibility.<sup><a href="#R7" rid="R7" class=" bibr popnode">7</a>,<a href="#R12" rid="R12" class=" bibr popnode">12</a></sup> Taking the 20% limit (including the 95% CI) set by the DVLA<sup><a href="#R9" rid="R9" class=" bibr popnode">9</a></sup> as a conservative approach, our data suggest that patients with a first seizure episode as a consequence of AIE due to NMDAR and LGI1 antibodies could be allowed to return to noncommercial driving after being seizure-free for 3 months.</p><p>In those driving regulations in which an acute symptomatic seizure leads to a shorter mandatory seizure-free interval compared with epilepsy or to first unprovoked seizures, this exception is limited to a single seizure event.<sup><a href="#R6" rid="R6" class=" bibr popnode">6</a>,<a href="#R8" rid="R8" class=" bibr popnode">8</a>,<a href="#R30" rid="R30" class=" bibr popnode">30</a></sup> The rationale for that regulation seems to be an analogy to recurrent unprovoked seizures in patients with seizures of unknown cause or a remote symptomatic structural cause, which carry a higher ReR compared with single seizures.<sup><a href="#R31" rid="R31" class=" bibr popnode">31</a></sup> There are insufficient data regarding multiple acute symptomatic seizures, except for acute symptomatic seizures presenting as status epilepticus, which are related to a higher risk of unprovoked seizures.<sup><a href="#R32" rid="R32" class=" bibr popnode">32</a></sup> In the acute phase of an AIE with NMDAR, LGI1, CASPR2, or GABA<sub>B</sub>R antibodies, recurrent rather than single seizures are the rule, and single seizures seem to be rare.<sup><a href="#R2" rid="R2" class=" bibr popnode">2</a>,<a href="#R28" rid="R28" class=" bibr popnode">28</a></sup> In contrast to recurrent unprovoked seizures of structural or unknown origin, our data demonstrate that recurrent seizures caused by AIE due to NMDAR, LGI1, and CASPR2 antibodies carry a more favorable prognosis for remission. We could not extract patients with single seizure from our data. As a surrogate, we tested for a potential effect of the duration of the seizure period on the ReR and did not find a correlation.</p><p>We think that our favorable results warrant a 3-month maximal driving ban in these patients similar to that for a (single) acute symptomatic seizure. Only the UK driving guidelines acknowledge the good prognosis of AIE by allowing patients with &#x0201c;acute encephalitic illness &#x02026; including limbic encephalitis associated with seizures&#x0201d; to drive after 6 months of seizure freedom.<sup><a href="#R30" rid="R30" class=" bibr popnode">30</a></sup> Our data provide evidence that may warrant reconsideration of this restriction.</p><p>For the selection of centers invited, we did not perform a systematic search of publications describing patient cohorts with AIE. Thus, we might have missed research groups with published data on these entities. Patients treated in specialized centers may represent a selection bias toward more severe cases.</p><p>Therapeutic approaches for seizures due to AIE reported in the literature are neither standardized nor uniform, making it difficult to classify and compare treatment regimens.<sup><a href="#R20" rid="R20" class=" bibr popnode">20</a>,<a href="#R33" rid="R33" class=" bibr popnode">33</a>,<a href="#R34" rid="R34" class=" bibr popnode">34</a></sup> However, the effect of ASM on seizures in AIE with antibodies against surface antigens seems to be marginal,<sup><a href="#R2" rid="R2" class=" bibr popnode">2</a>,<a href="#R35" rid="R35" class=" bibr popnode">35</a>,<a href="#R36" rid="R36" class=" bibr popnode">36</a></sup> with a low risk for seizure recurrence after stopping ASM.<sup><a href="#R25" rid="R25" class=" bibr popnode">25</a></sup> Thus, we decided not to consider the therapeutic approaches of the cooperating centers in this study. Therefore, we cannot draw a conclusion on the possible effects of different therapeutic strategies. We even cannot exclude that a small proportion of patients (e.g., with mild seizures only) were not treated at all or refused a long-term maintenance therapy. As a consequence, the ReR might be overestimated. On the other hand, final remission rates might be overestimated because we included only patients who had achieved 3 months of seizure freedom, suggesting a selection of patients with an a priori better prognosis. Thus, our outcome data cannot be compared with results of studies investigating therapy of unselected patients.</p><p>We did not assess the types of epileptic seizures. Some driving regulations allow patients with focal aware seizures to drive. However, we did not exclude these seizure types because driving permissions for such seizures usually require an observation period of more than 3 months, are limited to a semiology which does not interfere with driving ability (e.g., no motor or visual symptoms),<sup><a href="#R4" rid="R4" class=" bibr popnode">4</a>,<a href="#R6" rid="R6" class=" bibr popnode">6</a>,<a href="#R30" rid="R30" class=" bibr popnode">30</a></sup> and have to be the only seizure type during the whole observation period. In addition, many US state driving regulations still lack such an exception for focal aware seizures.<sup><a href="#R5" rid="R5" class=" bibr popnode">5</a></sup></p><p>In addition, we could not provide data to address severity of AIE (e.g., cognitive impairment, psychiatric symptoms, or admission to ICU) factors that might influence seizure outcome after AIE.<sup><a href="#R37" rid="R37" class=" bibr popnode">37</a></sup></p><p>We did not capture the number or frequency of seizures and the interval from the first seizure to the start of therapy. A longer delay between the initial AIE symptoms and the start of therapy has been shown to correlate with an unfavorable outcome.<sup><a href="#R2" rid="R2" class=" bibr popnode">2</a>,<a href="#R36" rid="R36" class=" bibr popnode">36</a>,<a href="#R38" rid="R38" class=" bibr popnode">38</a><a href="#R39" rid="R39" class=" bibr popnode">-</a><a href="#R40" rid="R40" class=" bibr popnode">40</a></sup> However, the duration of the seizure periods did not significantly influence the seizure recurrence risk in our data. In many previous studies on the prognosis of epilepsy and subsequent seizure risk, the number of seizures before seizure freedom could be achieved inversely correlated with seizure burden.<sup><a href="#R41" rid="R41" class=" bibr popnode">41</a></sup> Thus, in an individual patient, this low seizure risk may deviate from the risk of the whole cohort.</p><p>Seizure freedom was assessed retrospectively by patients' reports only. A prolonged video-EEG monitoring may be useful in a smaller proportion of patients to control for occurrence of unrecognized or unrecalled seizures, as suggested by a recent case series in LGI1 and CASPR2 patients.<sup><a href="#R42" rid="R42" class=" bibr popnode">42</a></sup> The effect of subclinical seizures identified in this manner on driving safety is unknown at this time; nonetheless, the existence of this phenomenon needs to be kept in mind in rendering final recommendations to patients and authorities. Thus, in individual situations, further evaluation to clarify seizure control may be prudent. This limitation, however, applies to all patients with seizures and epilepsy, regardless of the underlying etiology, and is not common practice for several reasons (availability, recording capacity, and undetermined lengths of programmed EEG monitoring).</p><p>Finally, it was not feasible to look at the effect of other potential consequences of AIE such as cognitive outcome that might affect driving safety.<sup><a href="#R43" rid="R43" class=" bibr popnode">43</a></sup> Therefore, the importance of this study lies in indicating that a significant proportion of patients with this condition do not warrant seizure-specific driving restrictions given the large number with seizure remission.</p><p>By using an international multicenter approach, we collected data from a large cohort of patients with seizures due to AIE against cell surface antigens. This endeavor has provided reliable information on the course of seizures in individual patients. We calculated seizure ReR estimates for the different types of antibodies for up to several years, including the outcomes after seizures had recurred. However, a very few patients had recurrences, so the numbers in the latter groups are small.</p><p>Because we have used data from clinical practice, our results could be used by driving experts and authorities to adopt driving regulations. Thus, our findings could be a step toward a more individualized assessment of driving eligibility.</p><p class="p p-last">Additional studies could investigate the influence of seizure types and frequency on seizure ReR, as well as the interval between the first seizure or other presenting symptoms and the start of therapy. In addition, more research regarding the type of immunotherapy and the value of ASM in patients with seizures due to AIE is needed.</p></div><div id="glossary-a.m.d" class="tsec sec"><h2 class="head no_bottom_margin" id="glossary-a.m.dtitle">Glossary</h2><div class="bk-sec"><div><table class="default-table glossary"><tbody><tr><td id="G1">AIE</td><td>autoimmune encephalitis</td></tr><tr><td id="G2">ASM</td><td>antiseizure medication</td></tr><tr><td id="G3">CASPR2</td><td>contactin-associated protein-like 2</td></tr><tr><td id="G4">CI</td><td>confidence intervals</td></tr><tr><td id="G5">COSY</td><td>chance of an occurrence of a seizure in the next year</td></tr><tr><td id="G6">DVLA</td><td>Driver and Vehicle Licensing Agency</td></tr><tr><td id="G7">FU</td><td>follow-up</td></tr><tr><td id="G8">GABA<sub>B</sub>R</td><td>gamma-aminobutyric-acid B receptor</td></tr><tr><td id="G9">KM</td><td>Kaplan-Meier</td></tr><tr><td id="G10">LGI1</td><td>leucine-rich glioma-inactivated 1</td></tr><tr><td id="G11">NMDAR</td><td>N-methyl-d-aspartate receptor</td></tr><tr><td id="G12">ReR</td><td>recurrence risk</td></tr></tbody></table></div></div></div><div id="A1" class="tsec sec"><h2 class="head no_bottom_margin" id="A1title">Appendix. Authors</h2><!--/article/back/app-group/app/--><p>
<!--table ft1--><!--table-wrap mode="anchored" t5--></p><div class="table-wrap anchored whole_rhythm" id="TU1"><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td rowspan="1" colspan="1">Name</td><td rowspan="1" colspan="1">Location</td><td rowspan="1" colspan="1">Contribution</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Anna Rada, MD</td><td rowspan="1" colspan="1">Department of Epileptology (Krankenhaus Mara), Medical School, Bielefeld University, Campus Bielefeld-Bethel, Germany</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; analysis or interpretation of data</td></tr><tr><td rowspan="1" colspan="1">Anne Hagemann, PhD</td><td rowspan="1" colspan="1">Society for Epilepsy Research, Bielefeld, Germany</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; analysis or interpretation of data</td></tr><tr><td rowspan="1" colspan="1">Charlotte Aaberg Poulsen, PhD</td><td rowspan="1" colspan="1">Department of Neurology, Odense University Hospital, Denmark</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Tobias Baumgartner, MD</td><td rowspan="1" colspan="1">Department of Epileptology, University Hospital Bonn, Germany</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Timea Berki, MD</td><td rowspan="1" colspan="1">Department of Immunology and Biotechnology, University of P&#x000e9;cs, Medical School, Hungary</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Morten Blaabjerg, MD, PhD</td><td rowspan="1" colspan="1">Department of Neurology, Odense University Hospital; Department of Clinical Research, University of Southern Denmark, Odense, Denmark</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Juliette Brenner, MD</td><td rowspan="1" colspan="1">Department of Neurology, Erasmus Medical Center, Rotterdam, Zuid-Holland, the Netherlands</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Jeffrey W. Britton, MD</td><td rowspan="1" colspan="1">Division of Epilepsy, Department of Neurology, Mayo Clinic, Rochester, MN</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Andrew Christiana, MD</td><td rowspan="1" colspan="1">NYU Comprehensive Epilepsy Center, New York</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Nicol&#x000e1;s L. Ciano-Petersen, MD</td><td rowspan="1" colspan="1">French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, H&#x000f4;pital Neurologique, UMR MELIS Inserm 1314 / CNRS 5284, Universit&#x000e9; Claude Bernard Lyon1, France</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Yvette Crijnen, MD</td><td rowspan="1" colspan="1">Department of Neurology, Erasmus Medical Center, Rotterdam, Zuid-Holland, the Netherlands</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Martin Eli&#x00161;&#x000e1;k, MD</td><td rowspan="1" colspan="1">Department of Neurology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Antonio Farina, MD</td><td rowspan="1" colspan="1">French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, H&#x000f4;pital Neurologique, UMR MELIS Inserm 1314 / CNRS 5284, Universit&#x000e9; Claude Bernard Lyon1, France</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Alec R. Friedman, MD</td><td rowspan="1" colspan="1">Department of Neurology, Columbia University Irving Medical Center (CUIMC)/New York Presbyterian Hospital, New York</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Zs&#x000f3;fia Hayden, MD</td><td rowspan="1" colspan="1">Department of Neurology, Medical School, University of P&#x000e9;cs, Hungary</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Julien H&#x000e9;bert, MD, MSc</td><td rowspan="1" colspan="1">Department of Neurology, Columbia University Irving Medical Center (CUIMC)/New York Presbyterian Hospital, New York; Division of Neurology, University of Toronto, Ontario, Canada</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Martin Holtkamp, MD</td><td rowspan="1" colspan="1">Epilepsy-Center Berlin-Brandenburg, Department of Neurology, Charit&#x000e9; - Universit&#x000e4;tsmedizin Berlin, Germany</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Zhen Hong, MD</td><td rowspan="1" colspan="1">Department of Neurology, West China Hospital, Sichuan University, Chengdu, China</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Jerome Honnorat, MD, PhD</td><td rowspan="1" colspan="1">French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, H&#x000f4;pital Neurologique, UMR MELIS Inserm 1314 / CNRS 5284, Universit&#x000e9; Claude Bernard Lyon1, France</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Maria Ilyas-Feldmann, MD, PhD</td><td rowspan="1" colspan="1">Epilepsy-Center Berlin-Brandenburg, Department of Neurology, Charit&#x000e9; - Universit&#x000e4;tsmedizin Berlin, Germany</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Sarosh R. Irani, BMBCh, MA (Oxon), DPhil, FRCP, FEAN</td><td rowspan="1" colspan="1">Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom; Department of Neurology and Neurosciences, Mayo Clinic, Jacksonville, FL</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Stjepana Kovac, MD</td><td rowspan="1" colspan="1">Department of Neurology with Institute of Translational Neurology, University Hospital M&#x000fc;nster, Germany</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Petr Marusic, MD</td><td rowspan="1" colspan="1">Department of Neurology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Sergio Mu&#x000f1;iz-Castrillo, MD, PhD</td><td rowspan="1" colspan="1">French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, H&#x000f4;pital Neurologique, UMR MELIS Inserm 1314 / CNRS 5284, Universit&#x000e9; Claude Bernard Lyon1, France</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Sudarshini Ramanathan, PhD</td><td rowspan="1" colspan="1">Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom; Translational Neuroimmunology Group, Kids Neuroscience Centre, Children's Hospital at Westmead; Faculty of Medicine and Health, University of Sydney; Department of Neurology, Concord Hospital, Sydney, Australia</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Kelsey M. Smith, MD</td><td rowspan="1" colspan="1">Division of Epilepsy, Department of Neurology, Mayo Clinic, Rochester, MN</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Claude Steriade, MD</td><td rowspan="1" colspan="1">NYU Comprehensive Epilepsy Center, New York</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Christine Strippel, MD</td><td rowspan="1" colspan="1">Department of Neurology with Institute of Translational Neurology, University Hospital M&#x000fc;nster, Germany</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Rainer Surges, MD</td><td rowspan="1" colspan="1">Department of Epileptology, University Hospital Bonn, Germany</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Maarten J. Titulaer, MD, PhD</td><td rowspan="1" colspan="1">Department of Neurology, Erasmus Medical Center, Rotterdam, Zuid-Holland, the Netherlands</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Christopher E. Uy, MD, FRCPC</td><td rowspan="1" colspan="1">Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom; Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, Canada</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Juna M de Vries, MD, PhD</td><td rowspan="1" colspan="1">Department of Neurology, Erasmus Medical Center, Rotterdam, Zuid-Holland, the Netherlands</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data</td></tr><tr><td rowspan="1" colspan="1">Christian G. Bien, MD</td><td rowspan="1" colspan="1">Department of Epileptology (Krankenhaus Mara), Medical School, Bielefeld University, Campus Bielefeld-Bethel; Laboratory Krone, Bad Salzuflen, Germany</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data</td></tr><tr><td rowspan="1" colspan="1">Ulrich Specht, MD</td><td rowspan="1" colspan="1">Department of Epileptology (Krankenhaus Mara), Medical School, Bielefeld University, Campus Bielefeld-Bethel, Germany</td><td rowspan="1" colspan="1">Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140633122052448"><a target="object" rel="noopener" href="/pmc/articles/PMC11160480/table/TU1/?report=objectonly">Open in a separate window</a></div></div><p>
</p></div><div id="sec-a.m.a" class="tsec bk-sec"><h2 class="head no_bottom_margin" id="sec-a.m.atitle">Study Funding</h2><!--/article/back/sec/--><p class="p p-first-last">The authors report no targeted funding.</p></div><div id="sec-a.m.b" class="tsec bk-sec"><h2 class="head no_bottom_margin" id="sec-a.m.btitle">Disclosure</h2><!--/article/back/sec/--><p class="p p-first-last">J. Britton reports an inventor agreement&#x02014;SEER Medical. J. H&#x000e9;bert received salary support through a grant from the American Epilepsy Society during his work on this project. M. Holtkamp received speaker's honoraria and/or consultancy fees from Angelini, Bial, Desitin, Eisai, Jazz Pharma, neuraxpharm, UCB, and Zogenix with the last 3 years. S.R. Irani has received honoraria from UCB, Immunovant, MedImmun, Roche, Janssen, Cerebral therapeutics, ADC therapeutics, Brain, Medlink Neurology and research support from CSL Behring, Janssen, UCB, and ONO Pharma, and is an inventor on 'Diagnostic Strategy to improve specificity of CASPR2 antibody detection (PCT/G82019/051257) and receives royalties on a licensed patent application for LGI1/CASPR2 testing as coapplicant (PCT/GB2009/051441) entitled 'Neurological Autoimmune Disorders'. P. Marusic have received fees as speaker or for serving on the advisory board from Angelini, Biogen, Egis, Eisai, UCB Pharma. These activities were not related to the content of this manuscript. S. Ramanathan has received research funding from the National Health and Medical Research Council (Australia), the Petre Foundation, the Brain Foundation (Australia), the Royal Australasian College of Physicians, and the University of Sydney. She was supported by an NHMRC Investigator Grant (GNT2008339). She serves as a consultant on an advisory board for UCB and Limbic Neurology, and has been an invited speaker for Biogen, Excemed, and Limbic Neurology. R. Surges has received fees as a speaker or for serving on the advisory board from Angelini, Arvelle, Bial, Desitin, Eisai, Janssen-Cilag GmbH, Livanova, Novartis, Precisis GmbH, UCB Pharma, UnEEG, and Zogenix. These activities were not related to the content of this manuscript. K. Smith receives research support from a grant from CURE Epilepsy. U. Specht is a co-chair of the Driving License Commission of the German Society of Epileptology. He reports no other disclosures. C. Steriade performs consulting for The Epilepsy Study Consortium&#x02014;salary support given to NYU for work provided to the following entities: Alterity, Baergic, Biogen, BioXcel, Cerebral, Cerevel, Eliem, Equilibre, Janssen, Longboard, Lundbeck, Marinus, NeuCyte, Neurocrine, Neuroelectrics, Ono, SK Life Science, and UCB. She also receives grants from NINDS, NCATS, NORD, UCB, and from Parekh Centre for Interdisciplinary Neurology outside the submitted work. J.M. de Vries, M.J. Titulaer, and J. Honnorat of this publication are members of the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases&#x02014;Project ID No 739543 (ERN-RITA; HCP Erasmus MC and HCP Lyon). M.J. Titulaer has filed a patent, on behalf of the Erasmus MC, for methods for typing neurological disorders and cancer, and devices for use therein, and has received research funds for serving on a scientific advisory board of Horizon Therapeutics, for consultation at Guidepoint Global LLC, for consultation at UCB, for teaching colleagues at Novartis. MT has received an unrestricted research grant from Euroimmun AG and from CSL Behring. C. Aaberg, J. Brenner, Y. S. Crijnen, T. Baumgartner, T. Berki, C.G. Bien, M. Blaabjerg, N.L. Ciano-Petersen, M. Elisak, A. Farina, A.R. Friedman, A. Hagemann, Z. Hayden, Z. Hong, M. Ilyas-Feldmann, S. Kovac, S. Mu&#x000f1;iz-Castrillo, A. Rada, Kelsey M. Smith, C. Strippel, and C. Uy report no disclosures relevant to the manuscript. Go to <a href="https://nn.neurology.org/content/0/0/e200225/tab-article-info" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Neurology.org/NN</a> for full disclosures.</p></div><div id="ref-list-a.m.e" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.m.etitle">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="mixed-citation">Jacoby A, Ring A, Whitehead M, Marson A, Baker GA. <span class="ref-title">Exploring loss and replacement of loss for understanding the impacts of epilepsy onset: a qualitative investigation</span>. <span class="ref-journal">Epilepsy Behav.</span>
2014;<span class="ref-vol">33</span>:59-68. doi: 10.1016/j.yebeh.2014.02.015
 [<a href="https://pubmed.ncbi.nlm.nih.gov/24632355" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.yebeh.2014.02.015" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epilepsy+Behav.&amp;title=Exploring+loss+and+replacement+of+loss+for+understanding+the+impacts+of+epilepsy+onset:+a+qualitative+investigation&amp;volume=33&amp;publication_year=2014&amp;pages=59-68&amp;pmid=24632355&amp;doi=10.1016/j.yebeh.2014.02.015&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="mixed-citation">de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, et al.. 
<span class="ref-title">Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis</span>. <span class="ref-journal">Neurology</span>. 2019;<span class="ref-vol">92</span>(<span class="ref-iss">19</span>):e2185-e2196. doi: 10.1212/WNL.0000000000007475
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6537134/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30979857" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1212%2FWNL.0000000000007475" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Evaluation+of+seizure+treatment+in+anti-LGI1,+anti-NMDAR,+and+anti-GABABR+encephalitis&amp;volume=92&amp;issue=19&amp;publication_year=2019&amp;pages=e2185-e2196&amp;pmid=30979857&amp;doi=10.1212/WNL.0000000000007475&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="mixed-citation">Steriade C, Britton J, Dale RC, et al.. 
<span class="ref-title">Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune&#x02010;associated epilepsy: conceptual definitions</span>. <span class="ref-journal">Epilepsia</span>. 2020;<span class="ref-vol">61</span>(<span class="ref-iss">7</span>):1341-1351. doi: 10.1111/epi.16571
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32544279" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fepi.16571" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epilepsia&amp;title=Acute+symptomatic+seizures+secondary+to+autoimmune+encephalitis+and+autoimmune&#x02010;associated+epilepsy:+conceptual+definitions&amp;volume=61&amp;issue=7&amp;publication_year=2020&amp;pages=1341-1351&amp;pmid=32544279&amp;doi=10.1111/epi.16571&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="mixed-citation">Austroads, National Transport Commission Australia (NTC). <span class="ref-journal">Assessing Fitness to Drive 2022 for Commercial and Private Vehicle Drivers</span>; 2022. Accessed October 2, 2023. <a href="https://austroads.com.au/publications/assessing-fitness-to-drive/ap-g56" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">austroads.com.au/publications/assessing-fitness-to-drive/ap-g56</a> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Assessing+Fitness+to+Drive+2022+for+Commercial+and+Private+Vehicle+Drivers&amp;publication_year=2022&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="mixed-citation">Ma BB, Bloch J, Krumholz A, et al.. 
<span class="ref-title">Regulating drivers with epilepsy in Maryland: results of the application of a United States consensus guideline</span>. <span class="ref-journal">Epilepsia</span>. 2017;<span class="ref-vol">58</span>(<span class="ref-iss">8</span>):1389-1397. doi: 10.1111/epi.13804
 [<a href="https://pubmed.ncbi.nlm.nih.gov/28569419" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fepi.13804" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epilepsia&amp;title=Regulating+drivers+with+epilepsy+in+Maryland:+results+of+the+application+of+a+United+States+consensus+guideline&amp;volume=58&amp;issue=8&amp;publication_year=2017&amp;pages=1389-1397&amp;pmid=28569419&amp;doi=10.1111/epi.13804&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="mixed-citation">M&#x000f6;ller L, Kr&#x000e4;mer G, Habermehl L, Menzler K, Knake S. <span class="ref-title">Driving regulations for epilepsy in Europe</span>. <span class="ref-journal">Seizure</span>. 2023;<span class="ref-vol">109</span>:83-91. doi: 10.1016/j.seizure.2023.05.016
 [<a href="https://pubmed.ncbi.nlm.nih.gov/37276778" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.seizure.2023.05.016" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Seizure&amp;title=Driving+regulations+for+epilepsy+in+Europe&amp;volume=109&amp;publication_year=2023&amp;pages=83-91&amp;pmid=37276778&amp;doi=10.1016/j.seizure.2023.05.016&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="mixed-citation">Second European Working Group on Epilepsy and Driving. <span class="ref-journal">Epilepsy and Driving in Europe. A Report of the Second European Working Group on Epilepsy and Driving, an Advisory Board to the Driving Licence Committee of the European Union. Final Report. [online]</span>. Accessed October 2, 2023. <a href="https://ec.europa.eu/transport/road_safety/system/files/2021-07/epilepsy_and_driving_in_europe_final_report_v2_en.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">ec.europa.eu/transport/road_safety/system/files/2021-07/epilepsy_and_driving_in_europe_final_report_v2_en.pdf</a> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Epilepsy+and+Driving+in+Europe.+A+Report+of+the+Second+European+Working+Group+on+Epilepsy+and+Driving,+an+Advisory+Board+to+the+Driving+Licence+Committee+of+the+European+Union.+Final+Report.+[online]&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="mixed-citation">European Union. <span class="ref-journal">Commission Directive 2009/113/EC of 25 August 2009 Amending Directive 2006/126/EC of the European Parliament and of the Council on Driving Licences</span>; 2009. L 223/231-235. Accessed October 2, 2023. <a href="https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:223:0031:0035:EN:PDF" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:223:0031:0035:EN:PDF</a> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Commission+Directive+2009/113/EC+of+25+August+2009+Amending+Directive+2006/126/EC+of+the+European+Parliament+and+of+the+Council+on+Driving+Licences&amp;publication_year=2009&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="mixed-citation">Bonnett LJ, Tudur-Smith C, Williamson PR, Marson AG. <span class="ref-title">Risk of recurrence after a first seizure and implications for driving: further analysis of the multicentre study of early Epilepsy and Single Seizures</span>. <span class="ref-journal">BMJ</span>. 2010;<span class="ref-vol">341</span>:c6477. doi: 10.1136/bmj.c6477
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2998675/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21147743" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1136%2Fbmj.c6477" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=Risk+of+recurrence+after+a+first+seizure+and+implications+for+driving:+further+analysis+of+the+multicentre+study+of+early+Epilepsy+and+Single+Seizures&amp;volume=341&amp;publication_year=2010&amp;pages=c6477&amp;pmid=21147743&amp;doi=10.1136/bmj.c6477&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="mixed-citation">Brown JW, Lawn ND, Lee J, Dunne JW. <span class="ref-title">When is it safe to return to driving following first-ever seizure?</span>. <span class="ref-journal">J Neurol Neurosurg Psychiatry</span>. 2015;<span class="ref-vol">86</span>(<span class="ref-iss">1</span>):60-64. doi: 10.1136/jnnp-2013-307529
 [<a href="https://pubmed.ncbi.nlm.nih.gov/24769470" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1136%2Fjnnp-2013-307529" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurol+Neurosurg+Psychiatry&amp;title=When+is+it+safe+to+return+to+driving+following+first-ever+seizure?&amp;volume=86&amp;issue=1&amp;publication_year=2015&amp;pages=60-64&amp;pmid=24769470&amp;doi=10.1136/jnnp-2013-307529&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="mixed-citation">Nishida T, Kawai K, Tachimori H. <span class="ref-title">Risks of seizure with fatal traffic crash at wheel in people with epilepsy</span>. <span class="ref-journal">Seizure</span>. 2020;<span class="ref-vol">76</span>:110-115. doi: 10.1016/j.seizure.2020.02.002
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32062321" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.seizure.2020.02.002" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Seizure&amp;title=Risks+of+seizure+with+fatal+traffic+crash+at+wheel+in+people+with+epilepsy&amp;volume=76&amp;publication_year=2020&amp;pages=110-115&amp;pmid=32062321&amp;doi=10.1016/j.seizure.2020.02.002&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="mixed-citation">Specht U, Bien CG. <span class="ref-title">Driving eligibility: implications of studies on seizure recurrence risk</span>. <span class="ref-journal">Acta Neurol Scand.</span>
2020;<span class="ref-vol">142</span>(<span class="ref-iss">6</span>):541-544. doi: 10.1111/ane.13327
 [<a href="https://pubmed.ncbi.nlm.nih.gov/32740908" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fane.13327" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Acta+Neurol+Scand.&amp;title=Driving+eligibility:+implications+of+studies+on+seizure+recurrence+risk&amp;volume=142&amp;issue=6&amp;publication_year=2020&amp;pages=541-544&amp;pmid=32740908&amp;doi=10.1111/ane.13327&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="mixed-citation">Engel J, Fisher RS, Krauss G, Krumholz A, Quigg MS. <span class="ref-journal">Expert Panel Recommendations: Seizure Disorders and Commercial Motor Vehicle Driver Safety. [online]</span>. <a href="https://www.fmcsa.dot.gov/sites/fmcsa.dot.gov/files/docs/Seizure-Disorders-MEP-Recommendations-v2-prot.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">fmcsa.dot.gov/sites/fmcsa.dot.gov/files/docs/Seizure-Disorders-MEP-Recommendations-v2-prot.pdf</a> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Expert+Panel+Recommendations:+Seizure+Disorders+and+Commercial+Motor+Vehicle+Driver+Safety.+[online]&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="mixed-citation">Liu X, Yan B, Wang R, et al.. 
<span class="ref-title">Seizure outcomes in patients with anti-NMDAR encephalitis: a follow-up study</span>. <span class="ref-journal">Epilepsia</span>. 2017;<span class="ref-vol">58</span>(<span class="ref-iss">12</span>):2104-2111. doi: 10.1111/epi.13929
 [<a href="https://pubmed.ncbi.nlm.nih.gov/29098690" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fepi.13929" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epilepsia&amp;title=Seizure+outcomes+in+patients+with+anti-NMDAR+encephalitis:+a+follow-up+study&amp;volume=58&amp;issue=12&amp;publication_year=2017&amp;pages=2104-2111&amp;pmid=29098690&amp;doi=10.1111/epi.13929&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="mixed-citation">Rada A, Birnbacher R, Gobbi C, et al.. 
<span class="ref-title">Seizures associated with antibodies against cell surface antigens are acute symptomatic and not indicative of epilepsy: insights from long-term data</span>. <span class="ref-journal">J Neurol.</span>
2021;<span class="ref-vol">268</span>(<span class="ref-iss">3</span>):1059-1069. doi: 10.1007/s00415-020-10250-6
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7914192/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33025119" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs00415-020-10250-6" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurol.&amp;title=Seizures+associated+with+antibodies+against+cell+surface+antigens+are+acute+symptomatic+and+not+indicative+of+epilepsy:+insights+from+long-term+data&amp;volume=268&amp;issue=3&amp;publication_year=2021&amp;pages=1059-1069&amp;pmid=33025119&amp;doi=10.1007/s00415-020-10250-6&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="mixed-citation">Smith KM, Dubey D, Liebo GB, Flanagan EP, Britton JW. <span class="ref-title">Clinical course and features of seizures associated with LGI1-antibody encephalitis</span>. <span class="ref-journal">Neurology</span>. 2021;<span class="ref-vol">97</span>(<span class="ref-iss">11</span>):e1141&#x02013;e1149. doi: 10.1212/WNL.0000000000012465
 [<a href="https://pubmed.ncbi.nlm.nih.gov/34233939" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1212%2FWNL.0000000000012465" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Clinical+course+and+features+of+seizures+associated+with+LGI1-antibody+encephalitis&amp;volume=97&amp;issue=11&amp;publication_year=2021&amp;pages=e1141-e1149&amp;pmid=34233939&amp;doi=10.1212/WNL.0000000000012465&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="mixed-citation">Dalmau J, Graus F. <span class="ref-title">Antibody-mediated encephalitis</span>. <span class="ref-journal">N Engl J Med.</span>
2018;<span class="ref-vol">378</span>(<span class="ref-iss">9</span>):840-851. doi: 10.1056/NEJMra1708712
 [<a href="https://pubmed.ncbi.nlm.nih.gov/29490181" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJMra1708712" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med.&amp;title=Antibody-mediated+encephalitis&amp;volume=378&amp;issue=9&amp;publication_year=2018&amp;pages=840-851&amp;pmid=29490181&amp;doi=10.1056/NEJMra1708712&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="mixed-citation">Wikipedia. <span class="ref-journal">List of Minimum Driving Ages</span>; 2022:24. Accessed December 28, 2022. <a href="https://en.wikipedia.org/w/index.php?title=List_of_minimum_driving_ages&#x00026;oldid=1129480335" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">en.wikipedia.org/w/index.php?title=List_of_minimum_driving_ages&#x00026;oldid=1129480335</a> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=List+of+Minimum+Driving+Ages&amp;publication_year=2022&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="mixed-citation">Gabilondo I, Saiz A, Gal&#x000e1;n L, et al.. 
<span class="ref-title">Analysis of relapses in anti-NMDAR encephalitis</span>. <span class="ref-journal">Neurology</span>. 2011;<span class="ref-vol">77</span>(<span class="ref-iss">10</span>):996-999. doi: 10.1212/WNL.0b013e31822cfc6b
 [<a href="https://pubmed.ncbi.nlm.nih.gov/21865579" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1212%2FWNL.0b013e31822cfc6b" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Analysis+of+relapses+in+anti-NMDAR+encephalitis&amp;volume=77&amp;issue=10&amp;publication_year=2011&amp;pages=996-999&amp;pmid=21865579&amp;doi=10.1212/WNL.0b013e31822cfc6b&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="mixed-citation">Guery D, Cousyn L, Navarro V, et al.. 
<span class="ref-title">Long-term evolution and prognostic factors of epilepsy in limbic encephalitis with LGI1 antibodies</span>. <span class="ref-journal">J Neurol.</span>
2022;<span class="ref-vol">269</span>(<span class="ref-iss">9</span>):5061-5069. doi: 10.1007/s00415-022-11162-3
 [<a href="https://pubmed.ncbi.nlm.nih.gov/35595970" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs00415-022-11162-3" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurol.&amp;title=Long-term+evolution+and+prognostic+factors+of+epilepsy+in+limbic+encephalitis+with+LGI1+antibodies&amp;volume=269&amp;issue=9&amp;publication_year=2022&amp;pages=5061-5069&amp;pmid=35595970&amp;doi=10.1007/s00415-022-11162-3&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="mixed-citation">Liu X, Guo K, Lin J, et al.. 
<span class="ref-title">Long&#x02010;term seizure outcomes in patients with autoimmune encephalitis: a prospective observational registry study update</span>. <span class="ref-journal">Epilepsia</span>. 2022;<span class="ref-vol">63</span>(<span class="ref-iss">7</span>):1812-1821. doi: 10.1111/epi.17245
 [<a href="https://pubmed.ncbi.nlm.nih.gov/35357695" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fepi.17245" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epilepsia&amp;title=Long&#x02010;term+seizure+outcomes+in+patients+with+autoimmune+encephalitis:+a+prospective+observational+registry+study+update&amp;volume=63&amp;issue=7&amp;publication_year=2022&amp;pages=1812-1821&amp;pmid=35357695&amp;doi=10.1111/epi.17245&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="mixed-citation">Shen CH, Fang GL, Yang F, et al.. 
<span class="ref-title">Seizures and risk of epilepsy in anti&#x02010;NMDAR, anti&#x02010;LGI1, and anti&#x02010;GABABR encephalitis</span>. <span class="ref-journal">Ann Clin Translational Neurol.</span>
2020;<span class="ref-vol">7</span>(<span class="ref-iss">8</span>):1392-1399. doi: 10.1002/acn3.51137 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7448167/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32710704" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Facn3.51137" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Clin+Translational+Neurol.&amp;title=Seizures+and+risk+of+epilepsy+in+anti&#x02010;NMDAR,+anti&#x02010;LGI1,+and+anti&#x02010;GABABR+encephalitis&amp;volume=7&amp;issue=8&amp;publication_year=2020&amp;pages=1392-1399&amp;doi=10.1002/acn3.51137&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="mixed-citation">Kaplan EL, Meier P. <span class="ref-title">Nonparametric estimation from incomplete observations</span>. <span class="ref-journal">J Am Stat Assoc.</span>
1958;<span class="ref-vol">53</span>(<span class="ref-iss">282</span>):457-481. doi: 10.2307/2281868 [<a href="//doi.org/10.2307%2F2281868" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Am+Stat+Assoc.&amp;title=Nonparametric+estimation+from+incomplete+observations&amp;volume=53&amp;issue=282&amp;publication_year=1958&amp;pages=457-481&amp;doi=10.2307/2281868&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="mixed-citation">Therneau TM, Grambsch PM, Pankratz VS. <span class="ref-title">Penalized survival models and frailty</span>. <span class="ref-journal">J Comput Graph Stat.</span>
2003;<span class="ref-vol">12</span>(<span class="ref-iss">1</span>):156-175. doi: 10.1198/1061860031365 [<a href="//doi.org/10.1198%2F1061860031365" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Comput+Graph+Stat.&amp;title=Penalized+survival+models+and+frailty&amp;volume=12&amp;issue=1&amp;publication_year=2003&amp;pages=156-175&amp;doi=10.1198/1061860031365&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="mixed-citation">Ilyas-Feldmann M, Pr&#x000fc;&#x000df; H, Holtkamp M. <span class="ref-title">Long-term seizure outcome and antiseizure medication use in autoimmune encephalitis</span>. <span class="ref-journal">Seizure</span>. 2021;<span class="ref-vol">86</span>:138-143. doi: 10.1016/j.seizure.2021.02.010
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33618141" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.seizure.2021.02.010" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Seizure&amp;title=Long-term+seizure+outcome+and+antiseizure+medication+use+in+autoimmune+encephalitis&amp;volume=86&amp;publication_year=2021&amp;pages=138-143&amp;pmid=33618141&amp;doi=10.1016/j.seizure.2021.02.010&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="mixed-citation">van Sonderen A, Arino H, Petit-Pedrol M, et al.. 
<span class="ref-title">The clinical spectrum of Caspr2 antibody-associated disease</span>. <span class="ref-journal">Neurology</span>. 2016;<span class="ref-vol">87</span>(<span class="ref-iss">5</span>):521-528. doi: 10.1212/WNL.0000000000002917
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4970662/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27371488" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1212%2FWNL.0000000000002917" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=The+clinical+spectrum+of+Caspr2+antibody-associated+disease&amp;volume=87&amp;issue=5&amp;publication_year=2016&amp;pages=521-528&amp;pmid=27371488&amp;doi=10.1212/WNL.0000000000002917&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="mixed-citation">Ari&#x000f1;o H, Armangue T, Petit-Pedrol M, et al.. 
<span class="ref-title">Anti-LGI1-associated cognitive impairment: presentation and long-term outcome</span>. <span class="ref-journal">Neurology</span>. 2016;<span class="ref-vol">87</span>(<span class="ref-iss">8</span>):759-765. doi: 10.1212/WNL.0000000000003009
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4999321/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27466467" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1212%2FWNL.0000000000003009" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Anti-LGI1-associated+cognitive+impairment:+presentation+and+long-term+outcome&amp;volume=87&amp;issue=8&amp;publication_year=2016&amp;pages=759-765&amp;pmid=27466467&amp;doi=10.1212/WNL.0000000000003009&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="mixed-citation">van Sonderen A, Thijs RD, Coenders EC, et al.. 
<span class="ref-title">Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up</span>. <span class="ref-journal">Neurology</span>. 2016;<span class="ref-vol">87</span>(<span class="ref-iss">14</span>):1449-1456. doi: 10.1212/WNL.0000000000003173
 [<a href="https://pubmed.ncbi.nlm.nih.gov/27590293" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1212%2FWNL.0000000000003173" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Anti-LGI1+encephalitis:+clinical+syndrome+and+long-term+follow-up&amp;volume=87&amp;issue=14&amp;publication_year=2016&amp;pages=1449-1456&amp;pmid=27590293&amp;doi=10.1212/WNL.0000000000003173&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="mixed-citation">Beghi E, Carpio A, Forsgren L, et al.. 
<span class="ref-title">Recommendation for a definition of acute symptomatic seizure</span>. <span class="ref-journal">Epilepsia</span>. 2010;<span class="ref-vol">51</span>(<span class="ref-iss">4</span>):671-675. doi: 10.1111/j.1528-1167.2009.02285.x
 [<a href="https://pubmed.ncbi.nlm.nih.gov/19732133" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fj.1528-1167.2009.02285.x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epilepsia&amp;title=Recommendation+for+a+definition+of+acute+symptomatic+seizure&amp;volume=51&amp;issue=4&amp;publication_year=2010&amp;pages=671-675&amp;pmid=19732133&amp;doi=10.1111/j.1528-1167.2009.02285.x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="mixed-citation">GOV.UK. <span class="ref-journal">Guidance: Neurological Disorders: Assessing Fitness to Drive (Plus Appendix B: Epilepsy and Seizure Rules and Further Guidance)</span>; 2022. Accessed October 2, 2023. <a href="https://www.gov.uk/guidance/neurological-disorders-assessing-fitness-to-drive" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">gov.uk/guidance/neurological-disorders-assessing-fitness-to-drive</a> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Guidance:+Neurological+Disorders:+Assessing+Fitness+to+Drive+(Plus+Appendix+B:+Epilepsy+and+Seizure+Rules+and+Further+Guidance)&amp;publication_year=2022&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="mixed-citation">Hauser WA, Rich SS, Lee JR-J, Annegers JF, Anderson VE. <span class="ref-title">Risk of recurrent seizures after two unprovoked seizures</span>. <span class="ref-journal">N Engl J Med.</span>
1998;<span class="ref-vol">338</span>(<span class="ref-iss">7</span>):429-434. doi: 10.1056/NEJM199802123380704
 [<a href="https://pubmed.ncbi.nlm.nih.gov/9459646" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJM199802123380704" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med.&amp;title=Risk+of+recurrent+seizures+after+two+unprovoked+seizures&amp;volume=338&amp;issue=7&amp;publication_year=1998&amp;pages=429-434&amp;pmid=9459646&amp;doi=10.1056/NEJM199802123380704&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span class="mixed-citation">Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. <span class="ref-title">Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus</span>. <span class="ref-journal">Ann Neurol.</span>
1998;<span class="ref-vol">44</span>(<span class="ref-iss">6</span>):908-912. doi: 10.1002/ana.410440609
 [<a href="https://pubmed.ncbi.nlm.nih.gov/9851435" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fana.410440609" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Neurol.&amp;title=Risk+of+unprovoked+seizure+after+acute+symptomatic+seizure:+effect+of+status+epilepticus&amp;volume=44&amp;issue=6&amp;publication_year=1998&amp;pages=908-912&amp;pmid=9851435&amp;doi=10.1002/ana.410440609&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">33. <span class="mixed-citation">Bien CG. <span class="ref-title">Management of autoimmune encephalitis</span>. <span class="ref-journal">Curr Opin Neurol.</span>
2021;<span class="ref-vol">34</span>(<span class="ref-iss">2</span>):166-171. doi: 10.1097/WCO.0000000000000909
 [<a href="https://pubmed.ncbi.nlm.nih.gov/33464762" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1097%2FWCO.0000000000000909" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Opin+Neurol.&amp;title=Management+of+autoimmune+encephalitis&amp;volume=34&amp;issue=2&amp;publication_year=2021&amp;pages=166-171&amp;pmid=33464762&amp;doi=10.1097/WCO.0000000000000909&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">34. <span class="mixed-citation">Ganesh A, Bartolini L, Wesley SF. <span class="ref-title">Worldwide survey of neurologists on approach to autoimmune encephalitis</span>. <span class="ref-journal">Neurol Clin Pract.</span>
2020;<span class="ref-vol">10</span>(<span class="ref-iss">2</span>):140-148. doi: 10.1212/CPJ.0000000000000701
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7156195/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32309032" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1212%2FCPJ.0000000000000701" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurol+Clin+Pract.&amp;title=Worldwide+survey+of+neurologists+on+approach+to+autoimmune+encephalitis&amp;volume=10&amp;issue=2&amp;publication_year=2020&amp;pages=140-148&amp;pmid=32309032&amp;doi=10.1212/CPJ.0000000000000701&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">35. <span class="mixed-citation">Irani SR, Stagg CJ, Schott JM, et al.. 
<span class="ref-title">Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype</span>. <span class="ref-journal">Brain</span>. 2013;<span class="ref-vol">136</span>(<span class="ref-iss">Pt 10</span>):3151-3162. doi: 10.1093/brain/awt212
 [<a href="https://pubmed.ncbi.nlm.nih.gov/24014519" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fbrain%2Fawt212" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Brain&amp;title=Faciobrachial+dystonic+seizures:+the+influence+of+immunotherapy+on+seizure+control+and+prevention+of+cognitive+impairment+in+a+broadening+phenotype&amp;volume=136&amp;issue=Pt+10&amp;publication_year=2013&amp;pages=3151-3162&amp;pmid=24014519&amp;doi=10.1093/brain/awt212&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">36. <span class="mixed-citation">Thompson J, Bi M, Murchison AG, et al.. 
<span class="ref-title">The importance of early immunotherapy in patients with faciobrachial dystonic seizures</span>. <span class="ref-journal">Brain</span>. 2018;<span class="ref-vol">141</span>(<span class="ref-iss">2</span>):348-356. doi: 10.1093/brain/awx323
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5837230/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29272336" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fbrain%2Fawx323" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Brain&amp;title=The+importance+of+early+immunotherapy+in+patients+with+faciobrachial+dystonic+seizures&amp;volume=141&amp;issue=2&amp;publication_year=2018&amp;pages=348-356&amp;pmid=29272336&amp;doi=10.1093/brain/awx323&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R37">37. <span class="mixed-citation">Titulaer MJ, McCracken L, Gabilondo I, et al.. 
<span class="ref-title">Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study</span>. <span class="ref-journal">Lancet Neurol.</span>
2013;<span class="ref-vol">12</span>(<span class="ref-iss">2</span>):157-165. doi: 10.1016/S1474-4422(12)70310-1
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3563251/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23290630" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS1474-4422(12)70310-1" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Neurol.&amp;title=Treatment+and+prognostic+factors+for+long-term+outcome+in+patients+with+anti-NMDA+receptor+encephalitis:+an+observational+cohort+study&amp;volume=12&amp;issue=2&amp;publication_year=2013&amp;pages=157-165&amp;pmid=23290630&amp;doi=10.1016/S1474-4422(12)70310-1&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R38">38. <span class="mixed-citation">Dubey D, Singh J, Britton JW, et al.. 
<span class="ref-title">Predictive models in the diagnosis and treatment of autoimmune epilepsy</span>. <span class="ref-journal">Epilepsia</span>. 2017;<span class="ref-vol">58</span>(<span class="ref-iss">7</span>):1181-1189. doi: 10.1111/epi.13797
 [<a href="https://pubmed.ncbi.nlm.nih.gov/28555833" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fepi.13797" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epilepsia&amp;title=Predictive+models+in+the+diagnosis+and+treatment+of+autoimmune+epilepsy&amp;volume=58&amp;issue=7&amp;publication_year=2017&amp;pages=1181-1189&amp;pmid=28555833&amp;doi=10.1111/epi.13797&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R39">39. <span class="mixed-citation">Matricardi S, Casciato S, Bozzetti S, et al.. 
<span class="ref-title">Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy</span>. <span class="ref-journal">J Neurol Neurosurg Psychiatry</span>. 2022;<span class="ref-vol">93</span>(<span class="ref-iss">11</span>):1194-1201. doi: 10.1136/jnnp-2022-329195 [<a href="https://pubmed.ncbi.nlm.nih.gov/35879055" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1136%2Fjnnp-2022-329195" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurol+Neurosurg+Psychiatry&amp;title=Epileptic+phenotypes+in+autoimmune+encephalitis:+from+acute+symptomatic+seizures+to+autoimmune-associated+epilepsy&amp;volume=93&amp;issue=11&amp;publication_year=2022&amp;pages=1194-1201&amp;doi=10.1136/jnnp-2022-329195&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R40">40. <span class="mixed-citation">Toledano M, Britton JW, McKeon A, et al.. 
<span class="ref-title">Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy</span>. <span class="ref-journal">Neurology</span>. 2014;<span class="ref-vol">82</span>(<span class="ref-iss">18</span>):1578-1586. doi: 10.1212/WNL.0000000000000383
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4013813/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24706013" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1212%2FWNL.0000000000000383" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Utility+of+an+immunotherapy+trial+in+evaluating+patients+with+presumed+autoimmune+epilepsy&amp;volume=82&amp;issue=18&amp;publication_year=2014&amp;pages=1578-1586&amp;pmid=24706013&amp;doi=10.1212/WNL.0000000000000383&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R41">41. <span class="mixed-citation">Chen Z, Brodie MJ, Liew D, Kwan P. <span class="ref-title">Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study</span>. <span class="ref-journal">JAMA Neurol.</span>
2018;<span class="ref-vol">75</span>(<span class="ref-iss">3</span>):279-286. doi: 10.1001/jamaneurol.2017.3949
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5885858/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29279892" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1001%2Fjamaneurol.2017.3949" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA+Neurol.&amp;title=Treatment+outcomes+in+patients+with+newly+diagnosed+epilepsy+treated+with+established+and+new+antiepileptic+drugs:+a+30-year+longitudinal+cohort+study&amp;volume=75&amp;issue=3&amp;publication_year=2018&amp;pages=279-286&amp;pmid=29279892&amp;doi=10.1001/jamaneurol.2017.3949&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R42">42. <span class="mixed-citation">Baumgartner T, Pitsch J, Olaciregui&#x02010;Dague K, et al.. 
<span class="ref-title">Seizure underreporting in LGI1 and CASPR2 antibody encephalitis</span>. <span class="ref-journal">Epilepsia</span>. 2022;<span class="ref-vol">63</span>(<span class="ref-iss">9</span>):e100&#x02013;e105. doi: 10.1111/epi.17338
 [<a href="https://pubmed.ncbi.nlm.nih.gov/35735209" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fepi.17338" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epilepsia&amp;title=Seizure+underreporting+in+LGI1+and+CASPR2+antibody+encephalitis&amp;volume=63&amp;issue=9&amp;publication_year=2022&amp;pages=e100-e105&amp;pmid=35735209&amp;doi=10.1111/epi.17338&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R43">43. <span class="mixed-citation">Wolfe PL, Lehockey KA. <span class="ref-title">Neuropsychological assessment of driving capacity</span>. <span class="ref-journal">Arch Clin Neuropsychol.</span>
2016;<span class="ref-vol">31</span>(<span class="ref-iss">6</span>):517-529. doi: 10.1093/arclin/acw050
 [<a href="https://pubmed.ncbi.nlm.nih.gov/27474026" ref="reftype=pubmed&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Farclin%2Facw050" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arch+Clin+Neuropsychol.&amp;title=Neuropsychological+assessment+of+driving+capacity&amp;volume=31&amp;issue=6&amp;publication_year=2016&amp;pages=517-529&amp;pmid=27474026&amp;doi=10.1093/arclin/acw050&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11160480&amp;issue-id=461565&amp;journal-id=2573&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">Neurology&#x00ae; Neuroimmunology &#x0026; Neuroinflammation</span> are provided here courtesy of <strong>American Academy of Neurology</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC11160480/pdf/NXI-2023-000585.pdf" class="int-view">PDF (526K)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/11160480/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/11160480/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="11160480" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11160480%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="a4myiZUQhUe5ZprLej5tSTDT4kTUpqpcyeo6WHrg8E8iW2NpFbqVeYAqHpqtvPO3">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11160480%2F&amp;text=Risk%20of%20Seizure%20Recurrence%20Due%20to%20Autoimmune%20Encephalitis%20With%20NMDAR%2C%20LGI1%2C%20CASPR2%2C%20and%20GABABR%20Antibodies%3A%20Implications%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11160480%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160480/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC11160480/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/38838283/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC11160480/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/38838283/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC11160480/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/11160480/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC11160480/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
